AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHealth CareGeographicals
Administration, OralDrug Administration ScheduleInjections, IntravenousUnited States Food and Drug AdministrationDrug Administration RoutesDose-Response Relationship, DrugRats, Sprague-DawleyTime FactorsAdministration, IntranasalRats, WistarInjections, IntraperitonealDisease Models, AnimalInjections, SubcutaneousAdministration, RectalLiverMice, Inbred C57BLBiological AvailabilityInjections, IntramuscularAdministration, TopicalInfusions, IntravenousHalf-LifeAdministration, IntravenousDrug InteractionsArea Under CurveInjections, IntraventricularMice, Inbred BALB CRats, Inbred StrainsAdministration, CutaneousTissue DistributionDogsDouble-Blind MethodCross-Over StudiesTreatment OutcomeBlood PressureAdministration, SublingualBrainAdministration, InhalationKidneyInfusions, ParenteralBody WeightRandom AllocationBehavior, AnimalDrug ToleranceMorphineRecombinant ProteinsPlant ExtractsInjectionsAnalysis of VarianceInjections, SpinalOrgan SizeMetabolic Clearance RateChromatography, High Pressure LiquidRNA, MessengerRabbitsMice, Inbred ICRLungRats, Inbred F344Analgesics, OpioidSelf AdministrationEthanolHeart RatePregnancyEstradiolMotor ActivityAntineoplastic AgentsDrug CombinationsMice, KnockoutHemodynamicsMice, Inbred StrainsDrug Evaluation, PreclinicalAnalgesicsDrug Therapy, CombinationEnzyme InhibitorsInjections, Intra-ArterialAdministration, BuccalSpleenPiperidinesProdrugsAntibodies, MonoclonalIntestinal AbsorptionBlood GlucoseDrug ApprovalAnti-Inflammatory Agents, Non-SteroidalDrug SynergismCocaineNaloxoneEatingUnited StatesDopamineGenetic TherapyNitric OxideCytokinesHydrocortisoneAbsorptionCells, CulturedLipopolysaccharidesImmunohistochemistryDelayed-Action PreparationsInsulinPain MeasurementPainBiotransformationTestosteroneAnti-Inflammatory AgentsAnti-Bacterial AgentsMicrodialysisDexamethasoneProgesteroneGenetic VectorsGrowth HormoneAdministration, IntravaginalInflammationTumor Necrosis Factor-alphaAnimals, NewbornAntioxidantsBody TemperatureModels, AnimalDrug Delivery SystemsNarcotic AntagonistsKineticsBileUnited States Department of Veterans AffairsGonadotropin-Releasing HormonePhytotherapyDrugs, Chinese HerbalVasodilator AgentsPyridinesLuteinizing HormoneDiabetes Mellitus, ExperimentalPiperazinesNeoplasms, ExperimentalProspective StudiesMice, NudeDevice ApprovalMice, TransgenicNeoplasm TransplantationApoptosisInfusion PumpsPyrazolesGlucocorticoidsRegional Blood FlowMethamphetamineSerotoninNorepinephrineAdjuvants, ImmunologicNeoplasmsDiazepamCorticosteroneSwineAnesthesiaChemistry, PharmaceuticalAdrenocorticotropic HormoneDrug CarriersCentral Nervous System StimulantsOvariectomyHyperalgesiaNeuroprotective AgentsMice, Inbred C3HLeukocyte CountHypnotics and SedativesGene ExpressionAnalgesics, Non-NarcoticIntestinesHaloperidolDrug-Induced Liver InjuryImidazolesAnti-Anxiety AgentsIndomethacinBrain ChemistryPlacebosSuppositoriesHypothalamusGene Expression RegulationSubstance Withdrawal SyndromeAdenoviridaeIodine RadioisotopesEdemaSignal TransductionNeuronsNitric Oxide SynthaseInfusion Pumps, ImplantableChorionic GonadotropinFecesBlotting, WesternNarcoticsOxidative StressClinical Trials as TopicErythropoietinAcute DiseaseHypoglycemic AgentsRats, Inbred LewEndotoxinsSheepImmunoglobulin GMyocardiumNicotineSulfonamidesAmphetamineInjections, IntradermalCorpus StriatumIntestinal Mucosa
Administration, Oral: The giving of drugs, chemicals, or other substances by mouth.Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Injections, Intravenous: Injections made into a vein for therapeutic or experimental purposes.United States Food and Drug Administration: An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.Drug Administration Routes: The various ways of administering a drug or other chemical to a site in a patient or animal from where the chemical is absorbed into the blood and delivered to the target tissue.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Rats, Sprague-Dawley: A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Administration, Intranasal: Delivery of medications through the nasal mucosa.Rats, Wistar: A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.Injections, Intraperitoneal: Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Injections, Subcutaneous: Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.Administration, Rectal: The insertion of drugs into the rectum, usually for confused or incompetent patients, like children, infants, and the very old or comatose.Liver: A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.Mice, Inbred C57BLBiological Availability: The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.Injections, Intramuscular: Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.Administration, Topical: The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example.Infusions, Intravenous: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.Half-Life: The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.Administration, Intravenous: Delivery of substances through VENIPUNCTURE into the VEINS.Drug Interactions: The action of a drug that may affect the activity, metabolism, or toxicity of another drug.Area Under Curve: A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992)Injections, Intraventricular: Injections into the cerebral ventricles.Mice, Inbred BALB CRats, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding.Administration, Cutaneous: The application of suitable drug dosage forms to the skin for either local or systemic effects.Tissue Distribution: Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Cross-Over Studies: Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed)Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Blood Pressure: PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.Administration, Sublingual: Administration of a soluble dosage form by placement under the tongue.Brain: The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.Administration, Inhalation: The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract.Kidney: Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.Infusions, Parenteral: The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping.Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.Random Allocation: A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects.Behavior, Animal: The observable response an animal makes to any situation.Drug Tolerance: Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL.Morphine: The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Plant Extracts: Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard.Injections: Introduction of substances into the body using a needle and syringe.Analysis of Variance: A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable.Injections, Spinal: Introduction of therapeutic agents into the spinal region using a needle and syringe.Organ Size: The measurement of an organ in volume, mass, or heaviness.Metabolic Clearance Rate: Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site.Chromatography, High Pressure Liquid: Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Rabbits: The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.Mice, Inbred ICRLung: Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.Rats, Inbred F344Analgesics, Opioid: Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS.Self Administration: Administration of a drug or chemical by the individual under the direction of a physician. It includes administration clinically or experimentally, by human or animal.Ethanol: A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES.Heart Rate: The number of times the HEART VENTRICLES contract per unit of time, usually per minute.Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.Estradiol: The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.Motor Activity: The physical activity of a human or an animal as a behavioral phenomenon.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Drug Combinations: Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.Mice, Knockout: Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.Hemodynamics: The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.Mice, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.Drug Evaluation, Preclinical: Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.Analgesics: Compounds capable of relieving pain without the loss of CONSCIOUSNESS.Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Enzyme Inhibitors: Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.Injections, Intra-Arterial: Delivery of drugs into an artery.Administration, Buccal: Administration of a soluble dosage form between the cheek and gingiva. It may involve direct application of a drug onto the buccal mucosa, as by painting or spraying.Spleen: An encapsulated lymphatic organ through which venous blood filters.Piperidines: A family of hexahydropyridines.Prodrugs: A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Intestinal Absorption: Uptake of substances through the lining of the INTESTINES.Blood Glucose: Glucose in blood.Drug Approval: Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.Anti-Inflammatory Agents, Non-Steroidal: Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.Drug Synergism: The action of a drug in promoting or enhancing the effectiveness of another drug.Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.Eating: The consumption of edible substances.United StatesDopamine: One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.Genetic Therapy: Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.Nitric Oxide: A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP.Cytokines: Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.Hydrocortisone: The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.Absorption: The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Lipopolysaccharides: Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed)Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Delayed-Action Preparations: Dosage forms of a drug that act over a period of time by controlled-release processes or technology.Insulin: A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).Pain Measurement: Scales, questionnaires, tests, and other methods used to assess pain severity and duration in patients or experimental animals to aid in diagnosis, therapy, and physiological studies.Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.Biotransformation: The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.Testosterone: A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.Anti-Inflammatory Agents: Substances that reduce or suppress INFLAMMATION.Anti-Bacterial Agents: Substances that reduce the growth or reproduction of BACTERIA.Microdialysis: A technique for measuring extracellular concentrations of substances in tissues, usually in vivo, by means of a small probe equipped with a semipermeable membrane. Substances may also be introduced into the extracellular space through the membrane.Dexamethasone: An anti-inflammatory 9-fluoro-glucocorticoid.Progesterone: The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.Genetic Vectors: DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.Growth Hormone: A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized.Administration, Intravaginal: The insertion of drugs into the vagina to treat local infections, neoplasms, or to induce labor. The dosage forms may include medicated pessaries, irrigation fluids, and suppositories.Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.Tumor Necrosis Factor-alpha: Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.Animals, Newborn: Refers to animals in the period of time just after birth.Antioxidants: Naturally occurring or synthetic substances that inhibit or retard the oxidation of a substance to which it is added. They counteract the harmful and damaging effects of oxidation in animal tissues.Body Temperature: The measure of the level of heat of a human or animal.Models, Animal: Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing.Drug Delivery Systems: Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.Narcotic Antagonists: Agents inhibiting the effect of narcotics on the central nervous system.Kinetics: The rate dynamics in chemical or physical systems.Bile: An emulsifying agent produced in the LIVER and secreted into the DUODENUM. Its composition includes BILE ACIDS AND SALTS; CHOLESTEROL; and ELECTROLYTES. It aids DIGESTION of fats in the duodenum.United States Department of Veterans Affairs: A cabinet department in the Executive Branch of the United States Government concerned with overall planning, promoting, and administering programs pertaining to VETERANS. It was established March 15, 1989 as a Cabinet-level position.Gonadotropin-Releasing Hormone: A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.Phytotherapy: Use of plants or herbs to treat diseases or to alleviate pain.Drugs, Chinese Herbal: Chinese herbal or plant extracts which are used as drugs to treat diseases or promote general well-being. The concept does not include synthesized compounds manufactured in China.Vasodilator Agents: Drugs used to cause dilation of the blood vessels.Pyridines: Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.Luteinizing Hormone: A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity.Diabetes Mellitus, Experimental: Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY.PiperazinesNeoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Device Approval: Process that is gone through in order for a device to receive approval by a government regulatory agency. This includes any required preclinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance. It is not restricted to FDA.Mice, Transgenic: Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Infusion Pumps: Fluid propulsion systems driven mechanically, electrically, or osmotically that are used to inject (or infuse) over time agents into a patient or experimental animal; used routinely in hospitals to maintain a patent intravenous line, to administer antineoplastic agents and other drugs in thromboembolism, heart disease, diabetes mellitus (INSULIN INFUSION SYSTEMS is also available), and other disorders.Pyrazoles: Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.Glucocorticoids: A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.Regional Blood Flow: The flow of BLOOD through or around an organ or region of the body.Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.Serotonin: A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator.Norepinephrine: Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.Adjuvants, Immunologic: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.Corticosterone: An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)Swine: Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).Anesthesia: A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.Chemistry, Pharmaceutical: Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.Adrenocorticotropic Hormone: An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP).Drug Carriers: Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.Central Nervous System Stimulants: A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.Ovariectomy: The surgical removal of one or both ovaries.Hyperalgesia: An increased sensation of pain or discomfort produced by mimimally noxious stimuli due to damage to soft tissue containing NOCICEPTORS or injury to a peripheral nerve.Neuroprotective Agents: Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.Mice, Inbred C3HLeukocyte Count: The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.Hypnotics and Sedatives: Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Analgesics, Non-Narcotic: A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS.Intestines: The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE.Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)Drug-Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.Imidazoles: Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).Anti-Anxiety Agents: Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits the enzyme cyclooxygenase necessary for the formation of prostaglandins and other autacoids. It also inhibits the motility of polymorphonuclear leukocytes.Brain Chemistry: Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states.Placebos: Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol.Suppositories: Medicated dosage forms that are designed to be inserted into the rectal, vaginal, or urethral orifice of the body for absorption. Generally, the active ingredients are packaged in dosage forms containing fatty bases such as cocoa butter, hydrogenated oil, or glycerogelatin that are solid at room temperature but melt or dissolve at body temperature.Hypothalamus: Ventral part of the DIENCEPHALON extending from the region of the OPTIC CHIASM to the caudal border of the MAMMILLARY BODIES and forming the inferior and lateral walls of the THIRD VENTRICLE.Gene Expression Regulation: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.Adenoviridae: A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases.Iodine Radioisotopes: Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.Edema: Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Neurons: The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM.Nitric Oxide Synthase: An NADPH-dependent enzyme that catalyzes the conversion of L-ARGININE and OXYGEN to produce CITRULLINE and NITRIC OXIDE.Infusion Pumps, Implantable: Implanted fluid propulsion systems with self-contained power source for providing long-term controlled-rate delivery of drugs such as chemotherapeutic agents or analgesics. Delivery rate may be externally controlled or osmotically or peristatically controlled with the aid of transcutaneous monitoring.Chorionic Gonadotropin: A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN).Feces: Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Narcotics: Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS.Oxidative Stress: A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi).Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.Acute Disease: Disease having a short and relatively severe course.Hypoglycemic Agents: Substances which lower blood glucose levels.Rats, Inbred LewEndotoxins: Toxins closely associated with the living cytoplasm or cell wall of certain microorganisms, which do not readily diffuse into the culture medium, but are released upon lysis of the cells.Sheep: Any of the ruminant mammals with curved horns in the genus Ovis, family Bovidae. They possess lachrymal grooves and interdigital glands, which are absent in GOATS.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Myocardium: The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.Nicotine: Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke.Sulfonamides: A group of compounds that contain the structure SO2NH2.Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.Injections, Intradermal: The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer.Corpus Striatum: Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE.Intestinal Mucosa: Lining of the INTESTINES, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. In the SMALL INTESTINE, the mucosa is characterized by a series of folds and abundance of absorptive cells (ENTEROCYTES) with MICROVILLI.
(1/222) Homing of stem cells to sites of inflammatory brain injury after intracerebral and intravenous administration: a longitudinal imaging study.

 (+info)

(2/222) Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events.

 (+info)

(3/222) Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

 (+info)

(4/222) Variability in the use of intravenous thrombolysis for mild stroke: experience across the SPOTRIAS network.

 (+info)

(5/222) Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine.

 (+info)

(6/222) A novel vitamin K1 2,3-epoxide reductase (VKOR) inhibitor, 3-acetyl-5-methyltetronic acid, reduces experimental glomerulonephritis.

Excessive proliferation of mesangial cells is observed in various types of glomerular disease including glomerulonephritis (GN), which is progressive in nature and eventually results in end-stage renal disease (ESRD). Vitamin K(1) 2,3-epoxide reductase (VKOR) and the vitamin K-dependent growth arrest-specific gene 6/Axl pathway play a key role in mesangial cell proliferation in GN. In the present study, we indicate the potential of a VKOR inhibitor, 3-acetyl-5-methyltetronic acid (AMT), to prevent the proliferation of glomerular mesangial cells and suppress the progression of GN. AMT was administered intravenously to rats once daily for 12 days and a mouse anti-Thy1 monoclonal antibody was injected intravenously after the AMT treatment on Day 6. Creatinine clearance (CCr) significantly increased and the albumin-to-creatinine ratio (ACR) significantly decreased in the AMT-treated group of the Thy-1 GN rats. In addition, glomerular and tubular damage was improved histopathologically in the AMT-treated group. AMT did not affect blood coagulation due to its unique pharmacokinetic properties. The concentration of AMT reached the IC(50) for VKOR in kidney, but not in liver. A novel VKOR inhibitor, AMT, reduced renal mesangial cell proliferation and could be a supportive treatment for GN.  (+info)

(7/222) Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients.

 (+info)

(8/222) Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.

 (+info)

AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaHealth Care
Administration, OralDrug Administration ScheduleInjections, IntravenousUnited States Food and Drug AdministrationDrug Administration RoutesDose-Response Relationship, DrugRats, Sprague-DawleyTime FactorsAdministration, IntranasalRats, WistarInjections, IntraperitonealDisease Models, AnimalInjections, SubcutaneousAdministration, RectalLiverMice, Inbred C57BLBiological AvailabilityInjections, IntramuscularAdministration, TopicalInfusions, IntravenousHalf-LifeAdministration, IntravenousDrug InteractionsArea Under CurveInjections, IntraventricularMice, Inbred BALB CAmrinoneEnalaprilatBarbituratesPleurodesisEtomidateInfusions, IntraosseousHistoplasma
*  Nasal administration
The nasal drug administration of naloxone was found to be as effective as the intravenous route. In opioid overdoses, where ... Nasal administration is a route of administration in which drugs are insufflated through the nose. It can be a form of either ... Nasal administration can therefore be used as an alternative to oral administration of for example tablets and capsules if a ... the variability in the amount absorbed after nasal administration should be comparable to that after oral administration. The ...
*  Vitamin C
With oral administration absorption efficiency decreases as amounts increase. Intravenous administration bypasses this. Doing ... Jacobs C, Hutton B, Ng T, Shorr R, Clemons M (February 2015). "Is there a role for oral or intravenous ascorbate (vitamin C) in ... The theory that large amounts of intravenous ascorbic acid can be used to treat late-stage cancer is - some forty years after ... Fritz H, Flower G, Weeks L, Cooley K, Callachan M, McGowan J, Skidmore B, Kirchner L, Seely D (July 2014). "Intravenous Vitamin ...
*  Labor induction
Intravenous administration of synthetic oxytocin preparations. A high dose does not seem to have greater benefits than a ... endocervical or extra-amniotic administration of prostaglandin, such as dinoprostone or misoprostol. Prostaglandin E2 is the ...
*  Peramivir
It is approved for intravenous administration. In October 2009, the U.S. Food and Drug Administration (FDA) issued an emergency ... for intravenous peramivir in December 2013. Peramivir (Rapivab) was approved for intravenous administration in Dec 2014. FDA: ... effective in intravenous treating 8 serious cases of swine flu. On October 23, the U.S. Food and Drug Administration (FDA) ... As of 2015, it is the only intravenous option for treating swine flu. An intramuscular (IM) peramivir phase II study for ...
*  Amrinone
Currently, only acute intravenous administration takes place. The effects of amrinone vary widely with species and experimental ... An IV administration of amrinone has been shown to increase cardiac output (CO) and stroke volume (SV) while concurrently ... Klein N.A.; Siskind S.J.; Frishman W.H.; Sonnelblick E.H.; LeJemtel T.H. (1981). "Hemodynamic Comparison of Intravenous ... An increase in cAMP with the administration of amrinone in vascular smooth muscle produces vasodilation by facilitating calcium ...
*  Metronidazole
Intravenous administration is commonly associated with thrombophlebitis. Infrequent adverse effects include: hypersensitivity ... The U.S. Food and Drug Administration suggests it only be used when necessary because it has been shown to be carcinogenic in ...
*  Belinostat
"Beleodaq (belinostat) For Injection, For Intravenous Administration. Full Prescribing Information" (PDF). Spectrum ... In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with ...
*  Route of administration
Common examples include oral and intravenous administration. Routes can also be classified based on where the target of action ... administration. Parenteral administration generally acts more rapidly than topical or enteral administration, with onset of ... Comparative biopharmaceutics of diazepam after single rectal, oral, intramuscular and intravenous administration in man". ... Strictly enteral administration (directly into the intestines) can be used for systemic administration, as well as local ( ...
*  Never events
Intravenous administration of mis-selected concentrated potassium chloride. NHS England produced a report on 148 reported never ... wrong route administration of chemotherapy; misplaced naso or orogastric tube not detected prior to use; inpatient suicide ... Patient death or serious disability associated with a hemolytic reaction due to the administration of ABO/HLA-incompatible ... wrong preparation or wrong route of administration) ...
*  Midazolam
Paradoxical reactions are particularly associated with intravenous administration. After nighttime administration of midazolam ... If intravenous midazolam is given too quickly, hypotension may occur. A "midazolam infusion syndrome" may result from high ... Intravenous midazolam is indicated for procedural sedation (often in combination with an opioid, such as fentanyl), for ... Atorvastatin administration along with midazolam results in a reduced elimination rate of midazolam. St John's wort decreases ...
*  Enalaprilat
... enalaprilat was only suitable for intravenous administration. This was overcome by the esterification of enalaprilat with ... The prolonged phase does not contribute to drug accumulation on repeated administration but is thought to be of pharmacological ... Peak plasma enalaprilat concentrations occur 2 to 4 hours after oral enalapril administration. Elimination thereafter is ... modifications was to give it ionisation characteristics that do not allow sufficient GI absorption for oral administration (in ...
*  Petroleum ether
Intravenous administration produces fever and local tissue damage. Petroleum-derived distillates have not been shown to be ...
*  Morphine
"Driving Miss Emma" is intravenous administration of morphine. Multi-purpose tablets (readily soluble hypodermic tablets that ... A 2009 review determined that, when the analyte is morphine and the limit of detection is 1 ng/ml, a 20 mg intravenous (IV) ... Recently, one study has used an animal model (hind-paw incision) to observe the effects of morphine administration on the acute ... The salts listed by the United States Drug Enforcement Administration for reporting purposes, in addition to a few others, are ...
*  Barbiturate overdose
Intravenous administration of saline, naloxone, thiamine, and/or glucose. Intubation and bemegride, or a hand-breather where ...
*  Codeine
"Analgesic effects of codeine-6-glucuronide after intravenous administration". European Journal of Pain. 1 (3): 185-90. doi: ... In August 2012, the United States Federal Drug Administration issued a warning about deaths in pediatric patients < 6 years old ... Urinary excretion rates of morphine and codeine following codeine administration". J. Anal. Toxicol. 15 (4): 161-6. doi:10.1093 ... Injectable codeine is available for subcutaneous or intramuscular injection only; intravenous injection is contraindicated as ...
*  Pleurodesis
"Fatal intravenous administration of a sterile talc slurry" (PDF). California Department of Public Health, Licensing and ... Pharmacy-prepared chemicals for pleurodesis should be clearly labeled "NOT FOR IV ADMINISTRATION" to avoid potentially fatal ... "Sterile Talc Powder For Intrapleural Administration Only". National Library of Medicine. Retrieved 25 June 2014. " ...
*  Codeine-6-glucuronide
"Analgesic effects of codeine-6-glucuronide after intravenous administration". European Journal of Pain. 1 (3): 185-190. doi: ...
*  Etomidate
Continuous intravenous administration of etomidate leads to adrenocortical dysfunction. The mortality of patients exposed to a ... As the only adrenal steroidogenesis inhibitor available for intravenous or parenteral administration, it is useful in ... It was developed at Janssen Pharmaceutica in 1964 and was introduced as an intravenous agent in 1972 in Europe and in 1983 in ... Pharmacokinetics of intravenous anesthetics". In Evers, Alex S.; Maze, Mervyn; Kharasch, Evan D. Anesthetic Pharmacology: Basic ...
*  Intraosseous infusion
A comparison of intravenous (IV), intramuscular (IM), and intraosseous (IO) routes of administration concluded that the ... Moore GP, Pace SA, Busby W (1989). "Comparison of intraosseous, intramuscular, and intravenous administration of ... The IO site can be used for 24 hours and should be removed as soon as intravenous access has been gained. Prolonged use of an ... Banerjee S, Singhi SC, Singh S, Singh M (1994). "The intraosseous route is a suitable alternative to intravenous route for ...
*  Prochlorperazine
Intravenous administration can be used to treat status migrainosus. Prochlorperazine is used to prevent vomiting caused by ...
*  Ketobemidone
Only about 13-24% is excreted unchanged after intravenous administration. Ketobemidone is 1-methyl-4-(3-hydroxyphenyl)-4- ... Determination of the Urinary Excretion of Ketobemidone and four of its Metabolites after Intravenous and Oral Administration in ...
*  Robert Spencer Stone
February 1937). The intravenous and intraduodenal administration of radio-sodium. Radiology 28: 178-188. Stone, Robert S., and ... February, 1937). The intravenous and intraduodenal administration of radio-sodium. Radiology 28: 178-188. Scott, K.G., (1968), ... 1937). "Excretion of radio-sodium following intravenous administration in man." Experimental Biology and Medicine 35.4: 595-598 ... from Physical Measurements of 200 and 1,000 Kilovolt X-rays 1 Excretion of radio-sodium following intravenous administration in ...
*  European Directive on Traditional Herbal Medicinal Products
Any medication that requires intravenous administration will not be authorised. Only herbal medicines that are intended to be ...
*  Trovafloxacin
... a prodrug of trovafloxacin for intravenous administration Quinolone Gootz, TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J ... In June 1999 the U.S. Food and Drug Administration advised doctors to limit the prescription of Trovan after it had been found ...
*  Digoxin immune fab
The product contains no preservatives and is intended for intravenous administration. Digibind is manufactured by ... especially with repeated administration. These reactions appear uncommon for example, in a study of 717 adults where only six ...
*  Cervical cancer
On June 15, 2006, the US Food and Drug Administration approved the use of a combination of two chemotherapy drugs, hycamtin and ... intravenous urography, and X-ray examination of the lungs and skeleton, and cervical conization. Stage 1A cervical cancer Stage ... In 2006, the U.S. Food and Drug Administration (FDA) approved the first preventive HPV vaccine, marketed by Merck & Co. under ... "FDA Approves First Drug Treatment for Late-Stage Cervical Cancer". U.S. Food and Drug Administration. 2006-06-15. Archived from ...
*  Histoplasma duboisii
Clinical response is typically apparent after 2 weeks of intravenous administration. Ketoconazole is also effective, starting ...
Iron bivalent, oral preparations Market (2014 - 2019) | Iron bivalent, oral preparations Market Report Trends, Analysis,...  Iron bivalent, oral preparations Market (2014 - 2019) | Iron bivalent, oral preparations Market Report Trends, Analysis,...
Iron bivalent, oral preparations market research report covering industry trends, market share, market growth analysis and projection by MIcroMarketMonitor.com. Iron bivalent, oral preparations market report includes,|Key question answered| What are market estimates and forecasts; which of Iron bivalent, oral preparations markets are doing well and which are not? and |Audience for this report| Iron bivalent, oral preparations companies.
http://www.micromarketmonitor.com/market-report/iron-bivalent-oral-preparations-reports-4290510059.html
AID 236679 - Maximum plasma concentration in rat after oral administration at 10 mg/kg dosage - PubChem  AID 236679 - Maximum plasma concentration in rat after oral administration at 10 mg/kg dosage - PubChem
BioAssay record AID 236679 submitted by ChEMBL: Maximum plasma concentration in rat after oral administration at 10 mg/kg dosage.
https://pubchem.ncbi.nlm.nih.gov/bioassay/236679
Norgestim eth estrad triphasic - best ethereum sites  Norgestim eth estrad triphasic - best ethereum sites
how to sell mined ethereum Status. Requirements/Limits necon 0.5/35 (28) oral tablet. 2. MO necon 1/35 (28) oral tablet. 2. MO necon 1/50 (28) oral tablet. 2. MO. NECON 10/11 (28) ORAL TABLET. 4. MO necon 7/7/7 oral tablet. 2. MO norethindrone-eth estradiol oral tablet. 2. MO norgestim-eth estrad triphasic oral tablet. 0.18/0.215/0.25 mg-25 mcg. 2. Jan 1, 2017 NORETHIN ACE-ETH. ESTRAD-FE tri-legest fe oral tablet 1-20/1-30/1-35 mg mcg trinessa (28) oral tablet 0.18/0.215/0.25 mg-35 mcg. NORGESTIM-ETH. ESTRAD TRIPHASIC tri-previfem oral tablet 0.18/0.215/0.25 mg-35 mcg. NORGESTIM-ETH. ESTRAD TRIPHASIC tri-sprintec oral tablet 0.18/0.215/ Mar 1, 2017 NORGESTIM-ETH ESTRAD. TRIPHASIC TAB 0.18/0.215/0.25. MG-35 MCG. NF. 1. Formulary Enhancement. N/A. ORENCIA CLCK INJ. 125MG/ML. NF. 1 + ST2. Formulary Enhancement. N/A. PRAMIPEXOLE TAB 3.75MG. NF. 1 + QL 93/31 Formulary Enhancement. N/A. PREDNISONE TAB 10 MG (21). NF. cryptowatch eth Nov 1, 2017 3. NORA-BE ORAL TABLET 0.35 MG. 2 norethindrone oral ...
http://aaroha.net/1847-norgestim-eth-estrad-triphasic.php
Cipro oral tablet 500 mg : Estrace Information  Cipro oral tablet 500 mg : Estrace Information
Opinion 24 July 2013 COLOBREATHE 1,662,500 IU,. Azithromycin 250 to 500 mg/day 1 YES dosage , MA. dosage , MA Ciprofloxacin 30 mg/kg/day.. Usual Adult Dose for Bacterial Infection. 250 to 500 mg orally 3. the required amount of oral suspension should be placed. amoxicillin antibiotic dosage.1) Les accords 7ème de dominante; 2) Les accords Majeurs 7 ouverts; 3) Transposition des accords 7 ouverts; 4)Tout les types daccords 7 barrés.ciprofloxacin hcl 500 mg oral tablet. ciprofloxacina dosis para itu, ciprofloxacin hcl 500 mg oral tablet, ciprofloxacina 500 mg sirve para infeccion urinaria.ciprofloxacine ciprofloxacine 500 mg ciprofloxacine effets secondaires ciprofloxacine. Ciprofloxacin 500 MG Oral Tablet. Oral tablet. Generic Name: Cipro.. (Cipro ) - cipro xr 500mg. Albania 6-1 villaggio nord ciprodar as prophylaxis in meningitis cipro xr 500mg price hc infection. Xl dose mg for tonsil stone ...
http://hackattackbr.tk/jate/cipro-oral-tablet-500-mg-406.php
A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole...  A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole...
This study investigated the safety and effectiveness of treatment with once daily oral administration of dexlansoprazole delayed-release capsules in adolescents
http://adisinsight.springer.com/trials/700220568?error=cookies_not_supported&code=34d1110e-9697-4509-84f3-60ad6e3ad684
Effects of chronic daily oral administration of 17ß-oestradiol and norethisterone on the isoforms of serum gonadotrophins in...  Effects of chronic daily oral administration of 17ß-oestradiol and norethisterone on the isoforms of serum gonadotrophins in...
Effects of chronic daily oral administration of 17ß-oestradiol and norethisterone on the isoforms of serum gonadotrophins in postmenopausal women ...
http://uu.diva-portal.org/smash/record.jsf?pid=diva2:83305
Vitamin K Oral Preparations Contagious After Eye Bacterial Drops Pink - mode eyes cultureguides  Vitamin K Oral Preparations Contagious After Eye Bacterial Drops Pink - mode eyes cultureguides
Spring is a time for renewal but for allergy sufferers its a time for perpetually sneezing rubbing itchy eyes swallowing to relieve the sore feeling in your throat. Red irritated eyes result that go away in three days to a week. Contains Ascorbyl Palmitate an oil soluble highly stable form of vitamin C Marie has been thinking that wearing contacts just isnt worth it. Check out these natural ways to heal pink eye! These really work to heal You might not need to go to the doctor for pink eye.. My head has a dull feeling and my eyes are sore and strained. If any one of these is you it pays to know the warning signs. Proliferative diabetic retinopathy is present as evidenced by Progressive ischemia leads to the pre-proliferative stage where "cotton wool spots" (nerve fie Urgent referral to an ophthalmologist Vitamin K Oral Preparations Contagious After Eye Bacterial Drops Pink is essential in patients with any level of. Wash face with ice cold water; Ice or cold packs; Limit sodium intake. ...
http://www.cultureguides.eu/ttudss-eyes/vitamin-k-oral-preparations-contagious-after-eye-bacterial-drops-pink/
NIOSHTIC-2 Publications Search - 00149200 - Effects of acute oral administration of lithium compounds on multiple schedule...  NIOSHTIC-2 Publications Search - 00149200 - Effects of acute oral administration of lithium compounds on multiple schedule...
The effects of acute oral administration of lithium (7439932) compounds on multiple schedule performance were studied in rats. Adult male Sprague-Dawley-rats were administered lithium-chloride (7447418) or lithium-carbonate (554132) orally in doses of 100, 200, or 300 milligrams per kilogram (mg/kg). Bar pressing performance on a multiple fixed ratio 20/fixed interval 5 minute schedule was measure
https://www.cdc.gov/niosh/nioshtic-2/00149200.html
Scientists develop new live oral cholera vaccine Video - Rediff Videos  Scientists develop new live oral cholera vaccine Video - Rediff Videos
Watch Scientists develop new live oral cholera vaccine video online on Rediff Videos. More videos of Indian, cholera, vaccine, National, Institute, of, Cholera, Chandigarh, and, Institute, of, Chemical, Biology are available. Watch and share videos and updates by Ani.
http://ishare.rediff.com/video/news-and-politics/scientists-develop-new-live-oral-cholera-vaccine/634884
The Case for Reactive Mass Oral Cholera Vaccinations  The Case for Reactive Mass Oral Cholera Vaccinations
Author Summary Cholera outbreaks have had catastrophic impact on societies for centuries. Despite more than half a century of advocacy for safe water, sanitation and hygiene, approximately 100,000 cholera cases and 5,000 deaths were reported in Zimbabwe between August 2008 and by July 2009. Safe and effective oral cholera vaccines have been licensed and used by affluent tourists for more than a decade to prevent cholera. We asked whether oral cholera vaccines could be used to protect high risk populations at a time of cholera. We calculated how many cholera cases could have been prevented if mass cholera vaccinations would have been implemented in reaction to past cholera outbreaks. We estimate that determined, well organized mass vaccination campaigns could have prevented 34,900 (40%) cholera cases and 1,695 deaths (40%) in Zimbabwe. In the sites with endemic cholera, Kolkata and Zanzibar, a significant number of cases could have been prevented but the impact would have been less dramatic. The barriers
http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0000952&imageURI=info:doi/10.1371/journal.pntd.0000952.t007
Quality Measure 6 Code List | MicroMD  Quality Measure 6 Code List | MicroMD
24 HR carvedilol phosphate 10 MG Extended Release Oral Capsule, 24 HR carvedilol phosphate 20 MG Extended Release Oral Capsule, 24 HR carvedilol phosphate 40 MG Extended Release Oral Capsule, 24 HR carvedilol phosphate 80 MG Extended Release Oral Capsule, 24 HR Hydrochlorothiazide 12.5 MG / metoprolol succinate 100 MG Extended Release Oral Tablet, 24 HR Hydrochlorothiazide 12.5 MG / metoprolol succinate 25 MG Extended Release Oral Tablet, 24 HR Hydrochlorothiazide 12.5 MG / metoprolol succinate 50 MG Extended Release Oral Tablet, 24 HR metoprolol succinate 100 MG Extended Release Oral Tablet, 24 HR metoprolol succinate 200 MG Extended Release Oral Tablet, 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, 24 HR metoprolol succinate 50 MG Extended Release Oral Tablet, 24 HR Propranolol Hydrochloride 120 MG Extended Release Oral Capsule, 24 HR Propranolol Hydrochloride 160 MG Extended Release Oral Capsule, 24 HR Propranolol Hydrochloride 60 MG Extended Release Oral Capsule, 24 HR ...
https://www.micromd.com/codes-006/
北京大学医学部机构知识库(IR@PKUHSC): Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa...  北京大学医学部机构知识库([email protected]): Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa...
center dot Rivaroxaban is an oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders.. center dot In single- and multiple-dose Phase I studies in White subjects, rivaroxaban was safe and demonstrated predictable, dose-dependent pharmacokinetics and pharmacodynamics.. WHAT THIS STUDY ADDS. center dot The Phase III programme with rivaroxaban is being conducted worldwide.. center dot Therefore, it is necessary to determine whether the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban are altered in patients of different ethnic origins.. center dot Dose-escalation studies were conducted to determine the safety, pharmacokinetics and pharmacodynamics of single and multiple doses of rivaroxaban in healthy Chinese subjects.. AIMS. To investigate the safety, pharmacokinetics and pharmacodynamics of rivaroxaban, an oral, direct Factor Xa (FXa) inhibitor, in healthy, male Chinese subjects.. METHODS. Two randomized, ...
http://ir.bjmu.edu.cn/handle/400002259/50519
Best Place To Buy Xeloda Online, Buy Xeloda Online Medicine h356m. in Daily Challenges Forum | dailymile  Best Place To Buy Xeloda Online, Buy Xeloda Online Medicine h356m. in Daily Challenge's Forum | dailymile
Best Place To Buy Xeloda Online, Buy Xeloda Online Medicine h356m. posted to the Daily Challenge group. Best Place To Buy Xeloda Online, Buy Xeloda Online Medicine ========================================================== Looking for Cheap Xeloda? Not a problem! TOP Offers Xeloda Online, Save YOUR MONEY! => Click Here to Buy Xeloda => http://all4health.in/page.php?sid=1&tds-key=xeloda Want to get a 5% discount? Your Coupon: 710095 LINK -->> http://all4health.in/page.php?sid=1&tds-key=xeloda Buy Xeloda NOW in our PHARMACY and Save YOUR MONEY! ========================================================== . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . - buy no prescription xeloda buy xeloda 120 tabs buy xeloda online with overnight delivery buy xeloda online buy cheap xeloda online buy xeloda online with next day shipping brand name of xeloda buy generic xeloda online buy xeloda no prescription required buy xeloda online uk buy xeloda online cod buy xeloda no doctor http:/
http://www.dailymile.com/groups/65-daily-challenge/discussions/388274-best-place-to-buy-xeloda-online-buy-xeloda-online-medicine-h356m
Oral dosage forms: providing solid and liquid oral dosage forms solutions for pharma | Roquette  Oral dosage forms: providing solid and liquid oral dosage forms solutions for pharma | Roquette
Oral dosage forms - Roquette can meet your needs for a wide range of dosage forms, solid oral dosage forms (tablets, capsules, sachets) and liquid oral dosage forms (syrups, solutions, liquid ampoules). | Roquette
https://www.roquette.com/pharma/oral-dosage/
Evaluation of Food Effects on the Oral Pharmacokinetics of Rosuvastati by Cheynne C. McLean  "Evaluation of Food Effects on the Oral Pharmacokinetics of Rosuvastati" by Cheynne C. McLean
Rosuvastatin is commonly prescribed for the treatment of hypercholesterolemia and exerts its effect through targeted accumulation in the liver. Current United States and Canadian dosing guidelines indicate no preference for fed or fasted rosuvastatin administration. In this study, we demonstrate for the first time that concomitant administration with food substantially reduced mean plasma rosuvastatin exposure in healthy Canadian East Asian and Caucasian subjects. In mice lower plasma level was also noted with food 2 hours after an oral rosuvastatin dose, while liver concentration was unaffected. Moreover, through retrospective analysis of rosuvastatin patient data, we conclude that taking an oral dose with food as opposed to on an empty stomach, does not significantly affect the cholesterol-lowering capacity of rosuvastatin. Since a common adverse event noted with statin therapy is muscle pain/damage associated with high circulating statin levels, our findings have the potential to serve as a novel and
https://ir.lib.uwo.ca/etd/3774/
Cipro 500 mg oral tablet : Calcium carbonate buy australia  Cipro 500 mg oral tablet : Calcium carbonate buy australia
West-Ward has ciprofloxacin 500 mg immediate-release tablets in 100 count.Ciprofloxacin tablet, USP is a synthetic broad spectrum antimicrobial agent for oral administration.The oral absorption of ciprofloxacin is enhanced by metoclopramide.. Buy ear drops without a prescription columbia beach hotel how does cialis work in the body dex price walgreens dex yeux.Ciprofloxacin given as an oral tablet is rapidly and well absorbed from the.Patient Information: Ciprofloxacin 500 MG Oral Tablet This medication is an antibiotic ...
http://eliteptc.tk/jijym/cipro-500-mg-oral-tablet-964.php
Review of challenges in optimizing oral anticoagulation therapy for stroke prevention in atrial fibrillation | RTI  Review of challenges in optimizing oral anticoagulation therapy for stroke prevention in atrial fibrillation | RTI
Oral anticoagulant therapy is the mainstay of stroke prevention in patients with atrial fibrillation; it is highly effective at reducing stroke risk, but its use can be limited by increased risk of bleeding. As new oral anticoagulants are available, barriers to optimal use of oral anticoagulation therapy warrant consideration by healthcare professionals and administrators who are seeking to optimize the quality of care for patients with atrial fibrillation.
https://www.rti.org/publication/review-challenges-optimizing-oral-anticoagulation-therapy-stroke-prevention-atrial
Buccal Patches: Boon To Oral Drug Delivery System  Buccal Patches: Boon To Oral Drug Delivery System
ABSTRACT. Buccal administration of drug provides a convenient route of administration for both systemic and local drug actions. The preferred site for retentive oral transmucosal delivery systems and for sustained and controlled release delivery device is the buccal mucosa. Rapid developments in the field of molecular biology and gene technology resulted in generation of many macromolecular drugs including peptides, proteins, polysaccharides and nucleic acids in great number possessing superior pharmacological efficacy with site specificity and devoid of untoward and toxic effects. However, the main impediment for the oral delivery of such drugs as potential therapeutic agents is their extensive presystemic metabolism, instability in acidic environment resulting into inadequate and erratic oral absorption. Direct access to the systemic circulation through the internal jugular vein bypasses drug from the hepatic first pass metabolism leading to high bioavailability. The objective of this article ...
http://www.ajptr.com/archive/volume-2/december-2012-issue-6/article-441.html
Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays  Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays
INTRODUCTION:. Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays constitute clinically valuable information.. OBJECTIVES:. To investigate the effects of apixaban on commonly used coagulation methods, and to evaluate anti-FXa assays for specific determination of the drug concentration.. MATERIALS AND METHODS:. Apixaban was added to plasma from healthy subjects in the concentration range 0-1000 μg L(-1) , and analyses were performed with different reagents for activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin, protein C, and protein S. A lupus anticoagulant assay and an APTT assay with varying phospholipid concentrations were used to study the phospholipid dependence.. RESULTS:. In general, apixaban showed fewer effects in vitro than have been shown for rivaroxaban, another direct FXa inhibitor. The ...
http://www.diva-portal.org/smash/record.jsf?pid=diva2:757216
Oral Chemotherapy  Oral Chemotherapy
This program explains oral chemotherapy. The program includes the following sections: what is the anatomy of cancer cells, how does chemotherapy work, how is oral chemotherapy taken, what are the side effects of oral chemotherapy, what are the effects of oral chemotherapy on the skin and nails, what are the effects of oral chemotherapy on fertility and sexuality and what are the other possible side effects of oral chemotherapy.
http://www.patient-education.com/english/topic/oral-chemotherapy
Amlodipine Besylate  Amlodipine Besylate
Hemodynamics. Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing. Although the acute intravenous administration of amlodipine decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina.. With chronic once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours. Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with amlodipine is also correlated with the height of pretreatment elevation; ...
https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=51382
Azithromycin Tablets Manufacturer,Azithromycin Oral Tablets Exporter  Azithromycin Tablets Manufacturer,Azithromycin Oral Tablets Exporter
MEDICO REMEDIES PVT. LTD. - Manufacturer and Exporter of Azithromycin Tablets, Azithromycin, Azithromycin Oral Tablet, Azithromycin Dihydrate Oral Tablet etc from India.
http://www.medicoremediesindia.net/azithromycin-tablets-2479317.html
Plasma Levels of Dantrolene following Oral Administration in Malignant Hyperthermia-susceptible Patients | Anesthesiology | ASA...  Plasma Levels of Dantrolene following Oral Administration in Malignant Hyperthermia-susceptible Patients | Anesthesiology | ASA...
Gregory C. Allen, M.D., F.R.C.P.C., Charles B. Cattran, M.D., F.R.C.P.C, Robert G. Peterson, M.D., Ph.D., Marcel Lalande, Ph.D.; Plasma Levels of Dantrolene following Oral Administration in Malignant Hyperthermia-susceptible Patients. Anesthes 1988;69(6):900-904. Download citation file:. ...
http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1953310
SYK Pathway | SYK Pathway  SYK Pathway | SYK Pathway
No biological or any other meaningful alterations in body weight, food consumption, or physical features Ipilimumab were noted. There were no significant dose-related effects in clinical laboratory examinations, and the treatment did not cause gross or microscopic changes in the tissues examined. The occasional presence of neoplasms did not reveal any consistent, dose-related trends in any group. The OECD (2004) derived from this study a NOAEL for chronic oral administration at approximately 2500 mg/kg bw/day. The NOAEL for surface-treated silica in a 6-month. dietary study was at 500 mg/kg bw/day, the only dose tested ( EPA, 2011). The toxic effects of nano- and micron-sized silica particles made from rice husk (and hence biogenic amorphous silica, not SAS) were studied by So et al. (2008). As this study is often discussed in the context of "nanosilica in food" it is nevertheless included in this review. The silica particles were about 30-90 nm. and 0.5-30 μm in size; their purity given as ...
http://sykpathway.com/category/syk/
Eating Garlic On An Empty Stomach Kills Malignant Tumor Cells In The Brain - Development Of Mental Health  Eating Garlic On An Empty Stomach Kills Malignant Tumor Cells In The Brain - Development Of Mental Health
Scientists have found that eating garlic on an empty stomach is a very effective way to prevent and treat many diseases. When you eat garlic on an empty stomach you increase its power against harmful bacteria because they are exposed to its direct action.. Garlic prevents aging and clogging the major and peripheral arteries, helping to reduce levels of bad cholesterol, protects against heart diseases, lowers blood pressure and has anti-inflammatory properties. It also reduces the synthesis of triglycerides in the liver, which helps prevent the development of atherosclerosis. Its consumption is recommended against diseases of the nervous system. Garlic aids in killing the cells of malignant tumors of the brain and strengthens the immune system.. ...
http://www.developmentofmentalhealth.com/eating-garlic-on-an-empty-stomach-kills-malignant-tumor-cells-in-the-brain/
China Powder and Oral Tablets Methandienon/Dianabol/D-Bol Muscle Strength - China Dianabol, Methandrostenolone  China Powder and Oral Tablets Methandienon/Dianabol/D-Bol Muscle Strength - China Dianabol, Methandrostenolone
China Powder and Oral Tablets Methandienon/Dianabol/D-Bol Muscle Strength, Find details about China Dianabol, Methandrostenolone from Powder and Oral Tablets Methandienon/Dianabol/D-Bol Muscle Strength - Changzhou Rongni Trade Co., Ltd.
http://czrnitrade.en.made-in-china.com/product/ZBLnHTNAfKVy/China-Powder-and-Oral-Tablets-Methandienon-Dianabol-D-Bol-Muscle-Strength.html
Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration -...  Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration -...
The pharmacokinetic profile of meloxicam in clinically healthy koalas (n = 15) was investigated. Single doses of meloxicam were administered intravenously (i.v.) (0.4 mg/kg; n = 5), subcutaneously (s.c.) (0.2 mg/kg; n = 1) or orally (0.2 mg/kg; n = 3), and multiple doses were administered to two groups of koalas via the oral or s.c. routes (n = 3 for both routes) with a loading dose of 0.2 mg/kg for day 1 followed by 0.1 mg/kg s.i.d for a further 3 days. Plasma meloxicam concentrations were quantified by high-performance liquid chromatography. Following i.v. administration, meloxicam exhibited a rapid clearance (CL) of 0.44 ± 0.20 (SD) L/h/kg, a volume of distribution at terminal phase (Vz) of 0.72 ± 0.22 L/kg and a volume of distribution at steady state (Vss) of 0.22 ± 0.12 L/kg. Median plasma terminal half-life (t1/2) was 1.19 h (range 0.71-1.62 h). Following oral administration either from single or repeated doses, only maximum peak plasma concentration (Cmax 0.013 ± 0.001 and 0.014 ± ...
http://onlinelibrary.wiley.com/doi/10.1111/jvp.12038/full?globalMessage=0
Rx Scoops | Drugs Detail  Rx Scoops | Drugs Detail
With the immediate release formulations, more than 90% of the orally administered dose is absorbed, and peak plasma concentrations of verapamil are observed 1 to 2 hours after dosing. Because of rapid biotransformation of verapamil during its first pass through the portalcirculation, the absolute bioavailability ranges from 20% to 35%. Chronic oral administration of the highest recommended dose (120 mg every 6 hours) resulted in plasma verapamil levels ranging from 125 to 400 ng/mL with higher values reported occasionally. A nonlinear correlation between the verapamil HCl dose administered and verapamil plasma levels does exist.. During initial dose titration with verapamil a relationship exists between verapamil plasma concentrations and the prolongation of the PR interval. However, during chronic administration this relationship may disappear. Thequantitative relationship between plasma verapamil concentrations and blood pressure reduction has not been fully characterized.. In a multiple dose ...
http://rxscoops.com/drugsdetail.php?drugsid=8116
Drinking Water On An Empty Stomach Treatment For Many Ailments  Drinking Water On An Empty Stomach Treatment For Many Ailments
... - Drinking water on an empty stomach soon after waking up is a healthy habit for people in Japan and this habit has many health benefits that were shown in several studies, water treatment provides a seriously positive effect against many ailments. The consumption of water first thing in the morning was shown to be
http://inminutes.com/drinking-water-empty-stomach-treatment-ailments/
United States Direct Factor Xa Inhibitor Market Report 2016 - RnR Market Research  United States Direct Factor Xa Inhibitor Market Report 2016 - RnR Market Research
United States Direct Factor Xa Inhibitor Market Report 2016 is a market research report available at US $3800 for a Single User PDF License from RnR Market Research Reports Library.
http://www.rnrmarketresearch.com/united-states-direct-factor-xa-inhibitor-market-report-2016-market-report.html
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta...  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta...
BACKGROUND: Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes. METHODS: We searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting searches to phase 3, randomised trials of patients with atrial fibrillation who were randomised to receive new oral anticoagulants or warfarin, and trials in which both efficacy and safety outcomes were reported. We did a prespecified meta-analysis of all 71 683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials. The main outcomes were stroke and systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortality, myocardial infarction, major bleeding, intracranial haemorrhage, and gastrointestinal bleeding. We calculated relative
http://hal.univ-brest.fr/hal-00935589
L-PROLINE AND CITRIC ACID CO-CRYSTALS OF (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLP- ...  L-PROLINE AND CITRIC ACID CO-CRYSTALS OF (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLP- ...
0095] To prepare the pharmaceutical compositions of this invention, one or more compounds of the present invention as the active ingredient is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules, caplets, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of ...
http://www.patentsencyclopedia.com/app/20120289694
Immunogenicity and protection from a single dose of internationally available killed oral cholera vaccine: a systematic review...  Immunogenicity and protection from a single dose of internationally available killed oral cholera vaccine: a systematic review...
In addition to improved water supply and sanitation, the two-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efficacy and effectiveness) conferred by a single OCV dose against cholera. The meta-analysis showed an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, after an OCV first dose. The estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufficient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggests otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.. ...
http://epicentre.msf.org/immunogenicity-and-protection-single-dose-internationally-available-killed-oral-cholera-vaccine-syst
Single dose pharmacokinetics of gestodene in women after intravenous and oral administration.  Single dose pharmacokinetics of gestodene in women after intravenous and oral administration.
Abstract Six healthy female volunteers (age 25 - 39 years) received 75 micrograms gestodene intravenously followed by 3 oral administrations of 25, 75 and 125 micrograms gestodene ..
https://www.omicsonline.org/references/single-dose-pharmacokinetics-of-gestodene-in-women-after-intravenous-and-oral-administration-539865.html
Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects - Full Text View -...  Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects - Full Text View -...
The purpose of the study is to evaluate the safety and tolerability of multiple ascending oral doses (MAD) of GLPG0555 given to healthy subjects for 13 days compared to placebo, and to evaluate the relative bioavailability and pharmacokinetics (PK) of two different aqueous suspensions of GLPG0555 administered for 3 days. Finally, it is aimed to characterize PK and pharmacodynamics (PD) of GLPG0555 after multiple oral administrations ...
https://clinicaltrials.gov/ct2/show/NCT01208753
Molecules | Free Full-Text | Repeated Oral Administration of Oleanolic Acid Produces Cholestatic Liver Injury in Mice | Notes  Molecules | Free Full-Text | Repeated Oral Administration of Oleanolic Acid Produces Cholestatic Liver Injury in Mice | Notes
Oleanolic acid (OA) is a triterpenoid and a fantastic molecule with many beneficial effects. However, high-doses and long-term use can produce adverse effects. This study aimed to characterize the hepatotoxic potential of OA. Mice were given OA at doses of 100-3,000 µmol/kg (45-1,350 mg/kg), po for 10 days, and the hepatotoxicity was determined by serum biochemistry, histopathology, and toxicity-related gene expression via real-time RT-PCR. Animal body weight loss was evident at OA doses of 1,000 µmol/kg and above. Serum alanine aminotransferase activities were increased in a dose-dependent manner, indicative of hepatotoxicity. Serum total bilirubin concentrations were increased, indicative of cholestasis. OA administration produced dose-dependent pathological lesions to the liver, including inflammation, hepatocellular apoptosis, necrosis, and feathery degeneration indicative of cholestasis. These lesions were evident at OA doses of 500 µmol/kg and above. Real-time RT-PCR revealed that OA produced
http://www.mdpi.com/1420-3049/18/3/3060/notes
Gastrointestinal absorption of heparins  Gastrointestinal absorption of heparins
Heparin, a highly sulfated and acidic glycosaminoglycan, has been clinically used in parenteral formulations to prevent and/or treat thromboembolic disorders for more than 90 years. Actions of heparin are not limited to anticoagulation and antithrombosis. Rather heparin has several other important actions which include fat clearing, antitumor and anti-inflammatory effects. However, use of heparin for such applications has been limited by its route of administration. Historically, it has been believed that heparin is not absorbed following oral administration and therefore is only available for clinical use by parenteral administration. This belief has been challenged several times by our laboratory and other researchers showing heparin binding to endothelium following oral administration as well as prevention of thrombosis and lowering blood pressure, etc. However, the site of oral heparin absorption and the mechanism responsible for absorption have not been investigated. This in vitro study was ...
https://ecommons.usask.ca/handle/10388/etd-12232009-141235
PREVPAC®(lansoprazole 30-mg capsules, amoxicillin 500-mg capsules, USP, and clarithromycin 500-mg tablets, USP) - Drug label...  PREVPAC®(lansoprazole 30-mg capsules, amoxicillin 500-mg capsules, USP, and clarithromycin 500-mg tablets, USP) - Drug label...
Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations. Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range. In two studies in which theophylline was administered with clarithromycin (a theophylline sustained-release formulation was dosed at either 6.5 mg/kg or 12 mg/kg together with 250 or 500 mg q12h clarithromycin), the steady-state levels of Cmax, Cmin, and the area under the serum concentration time curve (AUC) of theophylline increased about 20%.. Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine. Blood level monitoring of carbamazepine may be considered.. When clarithromycin and terfenadine were coadministered, plasma concentrations of the active acid metabolite of terfenadine ...
http://rxdrugsinfo.com/drug-info-label/prevpac
Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera...  Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera...
The hepatitis B virus core (HBc) virus-like particle (VLP) is known as one of the most immunogenic antigens and carrier vehicles in different immunization strategies. Recent findings are suggesting the potential of the HBc VLPs as an oral immunogen. Here, we focus on the induction of serum humoral responses by oral administration of HBc VLPs in preparations substantially free of lipopolysaccharide and immunomodulating encapsidated RNA. The full-length HBc antigen was used, because the C-terminal arginine-rich tail may contribute to the immunogenicity of the antigen as the region is involved in cell surface heparan sulfate binding and internalization of the protein. Serum antibody levels and isotypes were determined following oral administration of the HBc VLPs with the perspective of using the HBc VLP as an immunostimulatory and carrier molecule for epitopes of blood-borne diseases in oral immunization vaccination strategies. Following oral administration of the HBc VLP preparations to mice, a strong
https://www.semanticscholar.org/paper/Comparison-of-serum-humoral-responses-induced-by-o-Broos-Janssens/08f0e543a91b0f6458bce12b1636044cc99f1569
DRL MOXIFLOXACIN (film-coated tablets)  DRL MOXIFLOXACIN (film-coated tablets)
Following oral administration moxifloxacin is absorbed rapidly and almost completely. The absolute bioavailability amounts to approximately 90% after oral administration of a 400 mg dose. Pharmacokinetics are linear in the range of 50to1 200 mg single oral dose and up to 600 mg once daily dosing over 10 days. Steady state is reached within 3 days. Following a 400 mg oral dose, peak concentrations of 3,1 mg/L are reached within 0,5 to 4 h post administration. Peak and trough plasma concentrations at steady state (400 mg once daily) were 3,2 and 0,6 mg/L, respectively ...
http://home.intekom.com/pharm/dr-reddy/drlmoxi.html
Dr. Wes: Coumadin Beats Aspirin+Plavix  Dr. Wes: Coumadin Beats Aspirin+Plavix
The study was stopped early because of clear evidence of superiority of oral anticoagulation therapy. There were 165 primary events in patients on oral anticoagulation therapy (annual risk 3·93%) and 234 in those on clopidogrel plus aspirin (annual risk 5·60%; relative risk 1·44 (1·18-1.76; p=0.0003). Patients on oral anticoagulation therapy who were already receiving this treatment at study entry had a trend towards a greater reduction in vascular events (relative risk 1·50, 95% CI 1·19-1·89) and a significantly (p=0·03 for interaction) lower risk of major bleeding with oral anticoagulation therapy (1.30; 0.94-1.79) than patients not on this treatment at study entry (1·27, 0·85-1·89 and 0·59, 0·32-1·08, respectively ...
http://drwes.blogspot.com/2006/06/coumadin-beats-aspirinplavix.html
Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors - Progetto di formazione e...  Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors - Progetto di formazione e...
This pharmacokinetic study of nivolumab showed that there is little ethnic difference in the handling of nivolumab.Nivolumab was well tolerated in Korean patients.Background.This phase I study of nivolumab, an anti‐programmed cell death‐1 (anti‐PD‐1) monoclonal antibody, investigated the pharmacokinetics and safety of nivolumab in Korean patients with advanced solid tumors. Findings were compared with results from Japan and the U.S.Materials and Methods.In this two‐part study, patients received a single dose of nivolumab (1, 3, and 10 mg/kg; ONO‐4538‐13) and were followed up for 3 weeks. Those who met the required criteria proceeded to the second part (ONO‐4538‐14), and received the same dose as in part one every 2 weeks.Results.Six patients per dose level were enrolled (n = 18). The mean elimination half‐life of nivolumab among the groups ranged from 15.0 to 19.1 days. The maximum serum concentration and area under serum concentration-time curve increased almost ...
http://progetto-odin.it/phase-i-pharmacokinetic-study-of-nivolumab-in-korean-patients-with-advanced-solid-tumors/
Legere Pharmaceuticals: Oral administration of adenosine is effective for improving metabolic syndrome-related parameters [......  Legere Pharmaceuticals: "Oral administration of adenosine is effective for improving metabolic syndrome-related parameters [......
We have demonstrated previously that both acute and chronic oral administration of adenosine have novel functions such as anti-hypertensive effects and improved hyperlipidaemia in stroke-prone spontaneously hypertensive rats (SHRSP) fed a normal diet. The purpose of the present study was to investigate the effect of adenosine administration on metabolic syndrome-related parameters in SHRSP fed a high-fat diet. Six-week-old rats were divided into three groups, and were administered either water (control) or adenosine (10 or 100 mg/l) for 8 weeks. During this period, the rats had free access to a high-fat diet based on AIN-93M. The results showed that hypertension, plasma lipid, NO, insulin, glucose and urinary 8-hydroxy-2-deoxyguanosine levels improved significantly in both adenosine groups. The mRNA expression levels of genes involved in anti-oxidative activity and adenosine receptors were also altered in the adenosine groups. Administration of adenosine also increased plasma adiponectin ...
http://blog.legerepharm.com/2018/01/oral-administration-of-adenosine-is.html
Transitions With Novel Oral Anticoagulants - American College of Cardiology  Transitions With Novel Oral Anticoagulants - American College of Cardiology
Atrial fibrillation affects millions of patients in the United States and imparts a five-fold increase in stroke risk, as compared to the general population.1 Oral anticoagulation is the mainstay of treatment for thromboprophylaxis in atrial fibrillation patients. Until recently, vitamin K antagonists (warfarin in the US) were the sole option for patients at moderate to high risk for stroke or systemic embolism. Now there are several novel oral anticoagulants (NOAC) available in the US as alternatives to warfarin, with good evidence for their efficacy and safety.2-4 While dabigatran, rivaroxaban, and apixaban have been approved for use, there is little practical and even less published experience with these drugs in common clinical situations that require transitions onto or off of NOACs. We aim to discuss the risk of temporary interruptions, the possible hazard of transitioning from one anticoagulant to another, the pharmacokinetic properties of NOACs, and the data around bridging with oral ...
http://www.acc.org/latest-in-cardiology/articles/2014/07/18/15/31/transitions-with-novel-oral-anticoagulants
Prison Planet.com » Oral cholera vaccine loaded with GMOs to be tested on babies worldwide  Prison Planet.com » Oral cholera vaccine loaded with GMOs to be tested on babies worldwide
January 3, 2014. California-based vaccine manufacturer PaxVax has reportedly submitted an application to begin international trials of a novel oral cholera vaccine that contains live, genetically modified (GM) bacteria. VacTruth.com reports that the new vaccine is set to be tested on more than 1,000 individuals, many of whom are young children, in a three-part clinical trial series to take place throughout Australia.. In a recent application filing with the Australian Government, PaxVax makes plain its intent to administer the live, GM bacteria in both young and old and in every region of the country. Participants will be instructed to literally consume a cocktail of mercury-resistant, GM Shigella flexneri NR1 bacteria derived from the Vibrio cholera bacterial strain, which is recognized as the causative agent of the gastroenteritis disease known as cholera.. According to the filing, the GM cholera strain used in the vaccine has essentially been artificially neutralized to prevent the toxic ...
https://www.prisonplanet.com/oral-cholera-vaccine-loaded-with-gmos-to-be-tested-on-babies-worldwide.html
Lack of bioequivalence between two aciclovir tablets in healthy subjects - Golestan University of Medical Sciences Repository  Lack of bioequivalence between two aciclovir tablets in healthy subjects - Golestan University of Medical Sciences Repository
Objective: This study aimed to compare the systemic bioavailability of two aciclovir tablets, Rouz-Aciclovir (test) and Zovirax® (reference), in 12 healthy volunteers. Methods: In a crossover design, each subject received a single oral dose of aciclovir 400 mg followed by a 7-day washout period. Plasma concentrations of aciclovir were measured for up to 12 hours using a validated high-performance liquid chromatography method with a lower limit of quantification of 50 μg/L. Results: The mean values of maximum plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve from time 0 to 12 hours (AUC12) and from time 0 to infinity (AUC∞), and plasma half-life following administration of the test product were 999.6 μg/L, 2.08 h, 4911.2 μg/L • h, 5417.7 μg/L • h and 3.08 h, respectively, and for the reference product 775.8 μg/L, 2.58 h, 3862.1 μg/L • h, 4295.4 μg/L • h and 3.14 h, respectively. The test/reference geometric ratio for Cmax (90% CI) ...
http://eprints.goums.ac.ir/2349/
A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the...  A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the...
This phase 1b dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload, was conducted in sixteen transfusionally iron overloaded adult patients. FBS0701 was dosed daily for seven (7) days up to 32 mg/kg and was well tolerated at all dose levels. There were no serious adverse events associated with the drug. Pharmacokinetics showed dose-proportionality, Cmax within 60-90 minutes of dosing, rapid distribution at the predicted therapeutic doses and a plasma elimination half-life (t1/2) of approximately 19 hours. On the basis of these safety and pharmacokinetic data, FBS0701 warrants further clinical evaluation. ...
http://www.haematologica.org/content/early/2010/12/20/haematol.2010.034405
Prednisone oral dosage / Prozac et crise dangoisse  Prednisone oral dosage / Prozac et crise dangoisse
prednisolone pediatric dose asthma. Q: Can I take a double dose of 10mg prednisone to help with a mild. Oral Dexamethasone or Oral Prednisone for Pediatric Asthma.Prednisone prednisolone. Oral prednisone and mg prednisone tapering dose pack 40 mg prednisone vs. Hr prednisone 20 mg pregnancy. Oral dose for sale in.Prednisolone zentiva est un médicament générique sous forme de comprimé effervescent sécable (20)à base de Prednisolone (20 mg). Mis en vente en pharmacie.Where to buy prednisone in canada, bay prednisone, prednisone 10mg dosage directions,. oral prednisone dosage for poison ivy prednisone 5mg dose pack 48 tablets.la prise de la dose de 80 mg de prednisone, effets secondaires 40 mg de prednisone,,. kann man prednisone oral jelly apotheke kaufen. Tenir pour au cas par émission.Titre du document / Document title Biowaiver monographs for immediate release solid oral dosage forms: Prednisone Auteur(s) / Author(s) VOCT M. (1); DERENDORF H. (2.The dose is determined by the Prednisone ...
http://iaesl.tk/fana/prednisone-oral-dosage-455.php
New Supplier Approved by UN Health Agency for Oral Cholera Vaccines Will Double the Production  New Supplier Approved by UN Health Agency for Oral Cholera Vaccines Will Double the Production
As the world faced a dearth of oral cholera vaccines, the United Nations health agency announced that the supply of medication will double up to six million doses this year after it added another producer to its list of approved suppliers so that they can put up a fight against a disease that kills as many as 142,000 people every year
http://www.counselheal.com/articles/19638/20160112/un-health-agency-new-supplier-cholera-vaccination-meet-shortfall.htm
Nursing2013 survey results: Drug administration by enteral f... : Nursing2017  Nursing2013 survey results: Drug administration by enteral f... : Nursing2017
Guidelines for medication administration include the recommendation: "Liquid dosage forms should be used when available and if appropriate. Only immediate-release solid dosage forms may be substituted. Grind simple compressed tablets to a fine powder and mix with sterile water. Open hard gelatin capsules and mix powder with sterile water."21 Drug dosage forms include solids (capsules, tablets) and liquids (solutions, suspensions). Most solids are immediate-release products (compressed tablets, hard gelatin capsules) that contain the active drug molecule mixed with inactive ingredients. Immediate-release products are designed to release the drug within minutes of reaching the stomach following oral administration. But more and more drugs have been introduced as modified-release products (enteric-coated, extended-release, sustained-release).. Drugs manufactured for oral administration are designed specifically for the healthy GI tract. Destroying the carefully designed delivery mechanisms by ...
http://journals.lww.com/nursing/Fulltext/2013/12000/Nursing2013_survey_results__Drug_administration_by.10.aspx?WT.mc_id=HPxADx20100319xMP
UPTAKE PrPSc via Peyers Patches in Hamsters after Oral Exposure to Scrapie  UPTAKE PrPSc via Peyer's Patches in Hamsters after Oral Exposure to Scrapie
The disease-associated prion protein (PrPSc) has been detected in the ileal Peyers patches of lambs as early as one week after oral exposure to scrapie. In hamsters, the earliest reported time of PrPSc detection in the Peyers patches after oral exposure to scrapie is 69 days post-infection. To evaluate the acute uptake of inoculum and to investigate whether the Peyers patches constitute the primary site of entry for scrapie after oral exposure, hamsters were each exposed orally to 1 ml of a 10% brain homogenate from hamsters in the terminal stage of infection with the 263 K strain of the scrapie agent. PrPSc was demonstrated in the Peyers patches only a few days after exposure, i.e., much earlier than previously reported. This study supports the view that the Peyers patches constitute at least one of the primary entry sites of PrPSc after oral exposure to scrapie. Keywords: hamster; Peyers patches; prion disease; scrapie; sheep ...
http://www.vegsource.com/talk/madcow/messages/1000648.html
Plus it  Plus it
The early onset of the mean Cmax for the two major metabolites, penciclovir and M4, and their rate and extent of excretion in the urine indicated that SK1899 was rapidly absorbed from the gastrointestinal tract and extensively converted to its metabolites following oral administration to the rat and dog at doses up to 2 and 0.68 mmol/kg, respectively. However, the parent compound SK1899 was not detected in either plasma or urine, indicating that substantial first-pass metabolism of SK1899 occurred in both rats and dogs.. Following oral administration of SK1899 to both species, the ratios of the mean Cmax and AUC values for penciclovir to the corresponding values for M4 in plasma and the ratio of penciclovir to M4 concentrations excreted in urine decreased with increasing dose, suggesting that a dose-dependent decrease in the conversion of SK1899 to penciclovir occurred. In the rat, a 10-fold increase in dose from 0.2 to 2 mmol/kg led to a decrease in the ratios of penciclovir to M4 ...
http://dmd.aspetjournals.org/content/29/7/945
Evaluation of prochlorperazine buccal tablets (bukatel) and metoclopramide oral tablets in the treatment of acute emesis  Evaluation of prochlorperazine buccal tablets (bukatel) and metoclopramide oral tablets in the treatment of acute emesis
One group of patients received PCZ (3mg) huccal tablets. Bukatel, (Panacea Biotec Ltd) and the other group received metoclopramide oral tablets. Bukatel was placed high up along top of the gum on either side of the mouth where it was left to be dissolved. No other antiemetic therapy was given within 1 hour of taking either of the study drugs during the study period in the event of recurrence of vomiting. If the vomiting occurred after one hour, an additional dose of the study drug was Baseline general health was obtained by asking patients to complete a written health status questionnaire. The severity of the vomiting was scored as None (0), mild nausea only (1), moderate/ vomited once (2), severe vomiting repeatedly (3), very severe / incapacitating (4). Patients buccal mucosa was examined before and after the treatment using a scale: None (0), slight erythema (1). well defined erythema (2), severe erythema (3), severe erythema with ulccration(4). Relief from vomiting after drug intake was ...
http://finder-articles.com/p/pblsapepp.panaceabiotec.com1.html
Clinical outcomes of oral suspension versus delayed-release tablet formulations of posaconazole for prophylaxis of invasive...  Clinical outcomes of oral suspension versus delayed-release tablet formulations of posaconazole for prophylaxis of invasive...
TY - JOUR. T1 - Clinical outcomes of oral suspension versus delayed-release tablet formulations of posaconazole for prophylaxis of invasive fungal infections. AU - Furuno, Jon P.. AU - Tallman, Gregory B.. AU - Noble, Brie N.. AU - Bubalo, Joseph. AU - Forrest, Graeme N.. AU - Lewis, James S.. AU - Bienvenida, Ana F.. AU - Holmes, Courtney A.. AU - Weber, Bo R.. AU - McGregor, Jessina C.. PY - 2018/10/1. Y1 - 2018/10/1. N2 - Posaconazole is used for prophylaxis for invasive fungal infections (IFIs) among patients with hematologic malignancies. We compared the incidence of breakthrough IFIs and early discontinuation between patients receiving delayedrelease tablet and oral suspension formulations of posaconazole. This was a retrospective cohort study of patients receiving posaconazole between 1 January 2010 and 30 June 2016. We defined probable or proven breakthrough IFIs using the European Organization for Research and Treatment of Cancer (EORTC) criteria. Overall, 547 patients received 860 ...
https://ohsu.pure.elsevier.com/en/publications/clinical-outcomes-of-oral-suspension-versus-delayed-release-table
Abstract 18809: PER977: A Synthetic Small Molecule Which Reverses Over-Dosage and Bleeding by the New Oral Anticoagulants |...  Abstract 18809: PER977: A Synthetic Small Molecule Which Reverses Over-Dosage and Bleeding by the New Oral Anticoagulants |...
With regards to route of administration, drug interactions and predictability of bioactivity, the new oral anticoagulants (NOACs; direct factor Xa and IIa inhibitors) offer significant advantages over heparins and warfarin therapies. However, concern over serious bleeding, emergency procedures and potential over-dosage is heightened with the current lack of a specific reversal agent. PER977 is a synthetic small molecule rationally designed anticoagulant antidote. Reversal of anticoagulation induced bleeding was demonstrated in a rat tail transection model: weight-matched rats were overdosed with rivaroxaban, edoxaban, dabigatran, or apixaban, resulting in large increases in blood loss volume. PER977 was administered IV and after thirty minutes, blood loss volume was quantified. PER977 significantly decreased bleeding in vivo in rats treated with NOAC (Figure 1a). PT (for edoxaban, rivaroxaban, and apixaban) or aPTT (for dabigatran) and thromboelastography (TEG) (TEG- for edoxaban, Figure 1b) ...
http://circ.ahajournals.org/content/128/Suppl_22/A18809
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta...  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta...
Four RCTs were included; median follow-up ranged from 1.8 to 2.8 years. A total of 42,411 patients received the new oral anticoagulants and 29,272 received warfarin.. The new oral anticoagulants significantly reduced stroke or systemic embolic events by 19%, compared with warfarin (RR 0.81, 95% CI 0.73 to 0·91; Ι²=47%), mainly due to a reduction in haemorrhagic stroke (RR 0.49, 95% CI 0.38 to 0.64; Ι²=34%).. They significantly reduced all-cause mortality (RR 0.90, 95% CI 0.85 to 0.95; Ι²=0) and intracranial haemorrhage (RR 0.48, 95% CI 0.39 to 0.59; Ι²=32%), but increased gastrointestinal bleeding (RR 1.25, 95% CI 1.01 to 1.55; Ι²=74%).. There were no major differences in the analyses of stroke or systemic embolic events, for the important subgroups.. The overall reduction in stroke or systemic embolic events with low-dose regimens was similar to that with warfarin (RR 1.03, 95% CI 0.84 to 1.27; Ι²=70%), with a more favourable bleeding profile (RR 0.65, 95% CI 0.43 to 1.00; ...
http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?LinkFrom=OAI&ID=12013069847
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. - Nuffield Department of...  Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. - Nuffield Department of...
UNLABELLED: Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolerability were shown after 1 year. INTRODUCTION: Suboptimal adherence to daily and weekly oral bisphosphonates can potentially compromise therapeutic outcomes in postmenopausal osteoporosis. Although yet to be prospectively shown in osteoporosis, evidence from randomized clinical trials in several other chronic conditions shows that reducing dosing frequency enhances therapeutic adherence. Ibandronate is a new and potent bisphosphonate with antifracture efficacy proven for daily administration and also intermittent administration with a dose-free interval of |2 months. This report presents comparative data on the efficacy and safety of monthly and daily oral ibandronate regimens. MATERIALS AND METHODS: MOBILE is a 2-year, randomized, double-blind,
https://www.ndorms.ox.ac.uk/publications/126429
Ritalin Sr Oral Tablet, Extended Release 20Mg Drug Medication Dosage Information  Ritalin Sr Oral Tablet, Extended Release 20Mg Drug Medication Dosage Information
... Learn about the reported side effects, related class drugs, and how these medications will affect your daily lifestyle. Visit cvs.com for more details.
http://www.cvs.com/drug/ritalin-sr/oral-tablet-extended-release/20mg
Cholera Vaccination in Urban Haiti | The American Journal of Tropical Medicine and Hygiene  Cholera Vaccination in Urban Haiti | The American Journal of Tropical Medicine and Hygiene
Abstract. Successful and sustained efforts have been made to curtail the major cholera epidemic that occurred in Haiti in 2010 with the promotion of hygiene and sanitation measures, training of health personnel and establishment of treatment centers nationwide. Oral cholera vaccine (OCV) was introduced by the Haitian Ministry of Health as a pilot project in urban and rural areas. This paper reports the successful OCV pilot project led by GHESKIO Centers in the urban slums of Port-au-Prince where 52,357 persons received dose 1 and 90.8% received dose 2; estimated coverage of the at-risk community was 75%. This pilot study demonstrated the effort, community mobilization, and organizational capacity necessary to achieve these results in a challenging setting. The OCV intervention paved the way for the recent launching of a national cholera vaccination program integrated in a long-term ambitious and comprehensive plan to address Haiti's critical need in water security and sanitation.
http://www.ajtmh.org/content/journals/10.4269/ajtmh.13-0171
Studies on the anti-inflammatory and related pharmacological properties of the aqueous extract of Bridelia ferruginea stem bark...  Studies on the anti-inflammatory and related pharmacological properties of the aqueous extract of Bridelia ferruginea stem bark...
The anti-inflammatory profile of the aqueous extract of Bridelia ferruginea stem bark was investigated using both in vivo and in vitro models. The extract exhibited strong topical anti-inflammatory effect shown as inhibition of croton oil-induced ear oedema in mice, and reduced hind-paw swelling and growth retardation in the adjuvant-induced arthritis model in rats, following oral administration at 10, 20, 40 or 80 mg/kg. The extract (10-80 mg/kg, p.o.) caused an inhibition of increase in vascular permeability in both cyclophosphamide-induced haemorrhagic cystitis and acetic acid-induced vascular permeability in rats and mice, respectively. B. ferruginea produced stabilization of erythrocytes exposed to heat and stress-induced lysis. Antipyretic and analgesic properties of the extract were also observed.. ...
http://eprints.hud.ac.uk/id/eprint/8987/
Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers  Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers
Abstract:. The purpose of the present study was to assess the effect of resveratrol (RSV) treatment on the pharmacokinetics of diclofenac (DIC) in healthy human volunteers. The open-label, two period, sequential study was conducted in 12 healthy human volunteers. A single dose of RSV 500 mg was administered daily for 10 days during treatment phase. A single dose of DIC 100 mg was administered during control and after treatment phases under fasting conditions. The blood samples were collected after DIC dosing and analyzed by HPLC. Treatment with RSV significantly enhanced maximum plasma concentration (Cmax) (1.73 to 2.91 µg/mL), area under the curve (AUC) (5.05 to 9.95 µg h/mL), half life (T1/2) (1.12 to 1.76 h) and significantly decreased elimination rate constant (Kel) (0.71 to 0.41 h−1), apparent oral clearance (CL/F) (14.58 to 6.48 L/h) of DIC as compared to control. The geometric mean ratios for Cmax, AUC, T1/2, Kel and CL/F of DIC were 1.75, 2.12, 1.65, 0.61 and 0.47, respectively were ...
http://www.ahpa.org/News/Alerts/ScienceAlerts/TabId/104/ArtMID/549/ArticleID/584/Effect-of-Resveratrol-Treatment-on-the-Pharmacokinetics-of-Diclofenac-in-Healthy-Human-Volunteers.aspx
Veterinary Albendazole Oral Suspension - Veterinary Albendazole Oral Suspension Suppliers, Buyers, Wholesalers and...  Veterinary Albendazole Oral Suspension - Veterinary Albendazole Oral Suspension Suppliers, Buyers, Wholesalers and...
Veterinary Albendazole Oral Suspension directory ☆ Veterinary Albendazole Oral Suspension manufacturers, suppliers ☆ Veterinary Albendazole Oral Suspension buyers, importers, wholesalers, distributors
https://www.ecplaza.net/Veterinary-Albendazole-Oral-Suspension--everything
Antihistamine (Oral Route, Parenteral Route, Rectal Route) Precautions - Mayo Clinic  Antihistamine (Oral Route, Parenteral Route, Rectal Route) Precautions - Mayo Clinic
Antihistamines will add to the effects of alcohol and other CNS depressants (medicines that slow down the nervous system, possibly causing drowsiness). Some examples of CNS depressants are sedatives, tranquilizers, or sleeping medicine; prescription pain medicine or narcotics; barbiturates; medicine for seizures; muscle relaxants; or anesthetics, including some dental anesthetics. Check with your doctor before taking any of the above while you are using this medicine.. This medicine may cause some people to become drowsy or less alert than they are normally. Even if taken at bedtime, it may cause some people to feel drowsy or less alert on arising. Some antihistamines are more likely to cause drowsiness than others. Drowsiness is less likely with cetirizine, and rare with desloratadine and loratadine. Make sure you know how you react to the antihistamine you are taking before you drive, use machines, or do anything else that could be dangerous if you are not alert.. Antihistamines may cause ...
http://www.mayoclinic.org/drugs-supplements/antihistamine-oral-route-parenteral-route-rectal-route/precautions/drg-20070373?p=1
Human muscle response to sprint exercise and nutrient supply with focus on factors related to protein metabolism  Human muscle response to sprint exercise and nutrient supply with focus on factors related to protein metabolism
It is concluded that: Plasma leucine decreased and plasma and muscle ammonia increased following sprint exercise and more so in in males than females. Such changes might counteract a possible sprint exercise-induced stimulation of muscle protein synthesis. There was some activation of mTOR signalling in skeletal muscle following sprint exercise and more so in females than males. The larger increase in serum insulin and lower decrease in plasma leucine in females might have contributed to the enhanced signalling response in females. Oral ingestion of essential amino acids and carbohydrates, as compared to placebo, resulted in a markedly higher activation of Akt/mTOR signalling in skeletal muscle following sprint exercise. In contrast to the hypothesis, an oral ingestion of essential amino acids and carbohydrates did not result in an increased activation of hVps34 in skeletal muscle. However, this does not exclude the permissive role of hVps34 in mediating the amino acidinduced activation of ...
https://openarchive.ki.se/xmlui/handle/10616/45428
Lirias: Oral anticoagulant therapy: a precipitating factor in the pathogenesis of cholesterol embolization?  Lirias: Oral anticoagulant therapy: a precipitating factor in the pathogenesis of cholesterol embolization?
The authors describe three patients who developed a blue toe syndrome after initiation of oral anticoagulant therapy. Based on these observations and data in the literature, they discuss a possible relationship. They conclude that the vascular surgeon should be aware of this possibility and that oral anticoagulants should be used very carefully in the medical management of cholesterol embolization ...
https://lirias.kuleuven.be/handle/123456789/23797
Papers with the keyword use of rivaroxaban in children | Read by QxMD  Papers with the keyword use of rivaroxaban in children | Read by QxMD
Novel oral anticoagulants offer equivalent or improved therapeutic profiles compared with warfarin, with less risk of bleeding, no interactions with food, and no need for routine laboratory monitoring. Caution must be exercised in using these drugs in certain patient populations, for example, renal insufficiency, those receiving additional antithrombotic therapy, those with questionable compliance, children, and those with a high risk of gastrointestinal bleeding. One of the novel oral anticoagulants, rivaroxaban, is a direct Factor Xa inhibitor, used to reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis, and pulmonary embolism ...
https://www.readbyqxmd.com/keyword/43230
Drugs that Change Taste  Drugs that Change Taste
... There are many drugs that cause a change in your sense of taste. Some just have a weird taste but others can change the taste of everything you eat for hours afterword giving things a bitter, metallic taste. Some people call it medicine mouth, the drug companies refer to it as Taste perversion. Below is a list of the drugs that can alter or change your sense of taste. The drugs listed in bold print have an incident rate of 3% or more in users. ABILIFY® - Otsuka America (aripiprazole) Tablets ABILIFY® - Bristol-Myers Squibb (aripiprazole) Tablets ACTIQ® - Cephalon (oral transmucosal fentanyl citrate) ADALAT® CC - Bayer (nifedipine) Extended Release Tablets ADVAIR DISKUS - GlaxoSmithKline AGENERASE® - GlaxoSmithKline (amprenavir) Capsules AGENERASE® - GlaxoSmithKline (amprenavir) Oral Solution ALFERON N INJECTION® - Hemispherx Interferon alfa-n3 (human leukocyte derived) ALPHAGAN® P - Allergan (brimonidine tartrate
http://www.wineofthemonthclub.com/product/drugs-change-taste
Steven P. Treon MD Ph.D Waldenstroms  Steven P. Treon MD Ph.D Waldenstroms
Oral alkylating drugs, alone and in combination therapy with steroids, have been extensively evaluated in the upfront treatment of WM. The greatest experience with oral alkylator therapy has been with chlorambucil, which has been administered on both a continuous (i.e. daily dose schedule) as well as an intermittent schedule. Patients receiving chlorambucil on a continuous schedule typically receive 0.1 mg/kg per day, whilst on the intermittent schedule patients will typically receive 0.3 mg/kg for 7 days, every 6 weeks. In a prospective randomized study, Kyle et al.109 reported no significant difference in the overall response rate between these schedules, although interestingly the median response duration was greater for patients receiving intermittent versus continuously dosed chlorambucil (46 vs. 26 months). Despite the favorable median response duration in this study for use of the intermittent schedule, no difference in the median overall survival was observed. Moreover, an increased ...
http://stevenptreon.com/WM-6.htm
Clinical Trials: Phase I Dose-Escalation Study of Brutons Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell...  Clinical Trials: Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell...
Provides information to potential participants on the following clinical trial: Phase I Dose-Escalation Study of Brutons Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
http://www.oncologynurseadvisor.com/leukemia-clinical-trials/clinical-trials-phase-i-dose-escalation-study-of-brutons-tyrosine-kinase-btk-inhibitor-pci-32765-in-recurrent-b-cell-lymphoma/article/162839/
Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcit by Cynthia X Ma, Suresh G. Nair MD et al.  "Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcit" by Cynthia X Ma, Suresh G. Nair MD et al.
PURPOSE: A randomized three-arm phase II study was undertaken to evaluate the optimum administration schedule of pemetrexed and gemcitabine in chemotherapy-naïve patients with non-small-cell lung cancer. PATIENTS AND METHODS: Patients were randomly assigned to three schedules of pemetrexed 500 mg/m2 plus gemcitabine 1,250 mg/m2, separated by a 90-minute interval, on a 21-day cycle as follows: schedule A, pemetrexed followed by gemcitabine on day 1 and gemcitabine on day 8; schedule B, gemcitabine followed by pemetrexed on day 1 and gemcitabine on day 8; and schedule C, gemcitabine on day 1 and pemetrexed followed by gemcitabine on day 8. RESULTS: One hundred fifty-two eligible patients (schedule A, n = 59; schedule B, n = 31, and schedule C, n = 62) received a median of five (schedule A), two (schedule B), and four (schedule C) treatment cycles. Overall, 66% of patients experienced grade 3 or 4 neutropenia. Common grade 3 and 4 nonhematologic toxicities were dyspnea (11%), fatigue (16%), and
https://scholarlyworks.lvhn.org/medicine/719/
Amphotericin B Treatment for Indian Visceral Leishmaniasis: Response to 15 Daily versus Alternate-Day Infusions : Clinical...  Amphotericin B Treatment for Indian Visceral Leishmaniasis: Response to 15 Daily versus Alternate-Day Infusions : Clinical...
Background. For patients with Indian visceral leishmaniasis, amphotericin B deoxycholate is usually given as 15 alternate-day infusions of 1 mg/kg over 30 days (total dose, 15 mg/kg); daily treatment with 1 mg/kg for 20 days (total dose, 20 mg/kg) is also used. This study was done to address the unsettled therapeutic questions of administration schedule (alternate-day vs. daily administration) and dose (1 vs. 0.75 mg/kg) and to determine whether the duration of amphotericin B treatment in Bihar, India, can be shortened to 15 days.. Methods. To compare alternate-day versus daily administration and 1-mg/kg versus 0.75-mg/kg doses and to determine whether the duration of treatment could be abbreviated, Indian subjects randomly received 15 infusions of 1 mg/kg (group A; 245 patients) or 0.75 mg/kg (group B; 244 patients) on alternate days or 1 mg/kg (group C; 500 patients) or 0.75 mg/kg (group D; 496 patients) daily. Noninferiority testing compared 6-month cure rates using a 5% margin.. Results. ...
http://oxfordindex.oup.com/view/10.1086/520665
Phase I dose-escalation study of oral selective c-MET inhibitor EMD 1214063 in patients with advanced solid tumors | ...  Phase I dose-escalation study of oral selective c-MET inhibitor EMD 1214063 in patients with advanced solid tumors | ...
Purpose The cell surface receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor (HGF), mediate cell migration, survival and proliferation. EMD 1214063 is a highly selective, reversible and ATP-competitive c-Met inhibitor that causes growth inhibition and regression of HGF-dependent and HGF-independent tumors in pre-clinical models.. Methods This is a first-in-man dose-escalation study to establish the MTD of EMD 1214063. Eligible pts had advanced solid tumors not amenable to standard therapy. Following a 3 + 3 dose escalation scheme, pts were treated with once-daily oral EMD 1214063 according to two 21-day-cycle schedules, either days 1-14 followed by a 7-day rest (regimen 1, [R1]), or continuous 3 times weekly (regimen 2, [R2]). An optimised formulation was introduced in August 2011. Pd markers were evaluated in paired tumor biopsies using immunohistochemistry (IHC) and a Luminex based assay.. Results Until 3 November 2011, 50 pts had been treated; 27 in R1 and 23 in R2. The ...
http://oncologypro.esmo.org/Topics/Anti-Cancer-Agents-Biologic-Therapy/Drug-Development/Phase-I-dose-escalation-study-of-oral-selective-c-MET-inhibitor-EMD-1214063-in-patients-with-advanced-solid-tumors
Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5...  Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5...
TY - JOUR. T1 - Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats. AU - Monostori, Péter. AU - Kocsis, Gabriella F.. AU - Ökrös, Zsuzsanna. AU - Bencsik, Péter. AU - Czétényi, Orsolya. AU - Kiss, Zoltán. AU - Gellén, Balázs. AU - Bereczki, C.. AU - Ocsovszki, I.. AU - Pipis, Judit. AU - Pálóczi, János. AU - Sárközy, Márta. AU - Török, Szilvia. AU - Varga, I.. AU - Kiss, István. AU - Fodor, Eszter. AU - Csont, T.. AU - Ferdinándy, P.. AU - Túri, S.. PY - 2013/8. Y1 - 2013/8. N2 - Background: The development of erythropoiesis-stimulating agents (ESAs) with extended serum half-lives has allowed marked prolongation of the administration intervals. The level of oxidative stress is increased in chronic kidney disease, and is reportedly decreased after long-term ESA treatment. However, the effect of different dosing regimens of ESAs on oxidative stress has not been elucidated. Methods: ...
https://hungary.pure.elsevier.com/en/publications/different-administration-schedules-of-darbepoetin-alfa-affect-oxi
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer | Personalized...  FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer | Personalized...
For the second time this month, the FDA has given an approval to Genentechs PD-L1 inhibitor, Tecentriq.. On March 18, 2019, the FDA awarded the immunotherapy agent, Tecentriq (atezolizumab; Genentech), in combination with chemotherapy (carboplatin and etoposide), approval for the first-line treatment of adults with extensive-stage small-cell lung cancer (ES-SCLC).. As evidence of the rapidity with which the immunotherapy field is gaining ground in cancer treatment, this new approval comes only 10 days after the drug received an accelerated approval (in combination with nab-paclitaxel) for the treatment of triple-negative breast cancer. Not only is this the second approval for atezolizumab in close succession to the first, but it is the first novel treatment in 2 decades for ES-SCLC, an aggressive and deadly malignancy.. This latest approval was based on data from the phase 3 IMpower133 trial, which was the first study to show that initial treatment with the immunotherapy-based combination ...
http://www.personalizedmedonc.com/inthenews/fda-approves-tecentriq-plus-chemotherapy-for-first-line-treatment-of-extensive-stage-small-cell-lung-cancer/
Evaluation of an extended-interval gentamicin dosing protocol in neonates ≤ 33 weeks gestational age  Evaluation of an extended-interval gentamicin dosing protocol in neonates ≤ 33 weeks gestational age
We evaluated a simple, weight-based, extended-interval dosing (EID) gentamicin protocol specifically in neonates with gestational age ≤ 33 weeks, and its impact on sub-therapeutic peaks, elevated troughs, and simplification of dosing and monitoring as compared to a weight-based, multiple daily dose (MDD) protocol. Methodology. This study evaluated all infants with GA ≤ 33 weeks receiving gentamicin 1-year before EID protocol implementation in Jan 2002, and 1-year after. The MDD protocol used 2.5mg/kg every 8, 12, 18, or 24 hrs based on weight and age groupings. The EID protocol uses 3mg/kg q24 hours if weight , 1500gm and 4mg/kg if weight ≤ 1500gm. Desired trough was ≤ 2.0 mcg/ml and peak was 5 - 12 mcg/ml. Results. Characteristics were similar for the 123 MDD and 98 EID patients reviewed. The percentage of patients with at least 1 sub-therapeutic peak was lower with EID (7% vs. 20%, p,0.001); however the percentage with at least 1 elevated trough was similar (15% vs. 19%, p=0.219). ...
https://soar.wichita.edu/handle/10057/956
Comparative evaluation of six extended-interval gentamicin dosing regimens in premature and full-term neonates  Comparative evaluation of six extended-interval gentamicin dosing regimens in premature and full-term neonates
Purpose. Six extended-interval gentamicin dosing regimens were comparatively evaluated in premature and full-term neonates. Methods. Data regarding six physician-ordered dosing regimens of gentamicin for neonates in a hospital neonatal intensive care unit were collected and analyzed. Neonates of gestational age (GA) 29 weeks or younger received 4.5 mg/kg every 48 hours. Neonates of GA 30-34 weeks received one of three dosing regimens: 3.5, 4, or 4.5 mg/kg every 36 hours. Neonates of GA 35 weeks or older received either 3.5 or 4 mg/kg every 24 hours. Blood samples were collected 30 minutes before and 30 minutes after the third dose was infused for binary trough and peak level determinations, respectively. Results. Peak gentamicin concentrations in the target range were attained most often in neonates of GA 29 weeks or younger who received gentamicin 4.5 mg/kg every 48 hours, in neonates of GA 30-34 weeks treated with gentamicin 3.5 mg/kg every 36 hours, and in neonates of GA 35 weeks or older ...
http://connection.ebscohost.com/c/articles/56944926/comparative-evaluation-six-extended-interval-gentamicin-dosing-regimens-premature-full-term-neonates
United States Bolus Infusion Insulin Pump Market 2016 Market Growth, Trends, Demand, Share, Analysis to 2021 | Business  United States Bolus Infusion Insulin Pump Market 2016 Market Growth, Trends, Demand, Share, Analysis to 2021 | Business
Purchase a copy of United States Bolus Infusion Insulin Pump Market Research Report at: http://www.marketreportsworld.com/purchase/10263905. Further in the United States Bolus Infusion Insulin Pump Market Industry Analysis report, the United States Bolus Infusion Insulin Pump Market is examined for price, cost and gross. These three points are analysed for types, companies and regions. In continuation with this data sale price is for various types, applications and region is also included. The United States Bolus Infusion Insulin Pump Market for major regions is given. Additionally, type wise and application wise consumption figures are also given.. With the help of supply and consumption data, gap between these two is also explained.. Get Discount on United States Bolus Infusion Insulin Pump Market Research Report at: http://www.marketreportsworld.com/enquiry/request-discount/10263905. To provide information on competitive landscape, this report includes detailed profiles of United States Bolus ...
http://beforeitsnews.com/business/2017/02/united-states-bolus-infusion-insulin-pump-market-2016-market-growth-trends-demand-share-analysis-to-2021-3155766.html
Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Childrens...  Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's...
TY - JOUR. T1 - Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors. T2 - A report from the Childrens Oncology Group Phase 1 Pilot Consortium (ADVL1213). AU - Norris, Robin E.. AU - Fox, Elizabeth. AU - Reid, Joel M. AU - Ralya, Andrew. AU - Liu, Xiaowei W.. AU - Minard, Charles. AU - Weigel, Brenda J.. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Background: Ontuxizumab is a humanized IgG monoclonal antibody that targets the cell-surface glycoprotein endosialin (tumor endothelial marker-1[TEM-1]/CD248) found on activated mesenchymal cells and certain tumors. Ontuxizumab binding to endosialin may interfere with platelet-derived growth factor signaling, prevent tumor stroma organization, and prevent new vessel formation. Methods: Ontuxizumab was administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle at three dose levels (4, 8, and 12 mg/kg). Further dose escalation to 16 mg/kg was planned if the maximum tolerated dose (MTD) was not reached and the ...
https://mayoclinic.pure.elsevier.com/en/publications/phase-1-trial-of-ontuxizumab-morab-004-in-children-with-relapsed-
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors | Cancer Discovery  Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors | Cancer Discovery
Taselisib was dosed in patients from 3 to 16 mg, administered once daily. One of 10 patients treated at 12 mg and 2 of 11 patients treated at 16 mg experienced AEs that qualified as DLTs. Although 16 mg did not exceed the MTD as defined by DLTs in cycle 1, no higher dose beyond 16 mg was tested based upon the overall tolerability of taselisib that included assessment of the frequency/severity of AEs outside of the DLT window. Patients treated at the higher doses (12-16 mg) experienced increased frequency of fatigue and hyperglycemia.. The overall AE profile for taselisib in the current study was largely consistent with other PI3K inhibitors (14-16). Buparlisib (BKM120), a pan-class inhibitor that targets all four isomers of PI3K, had rash, hyperglycemia, diarrhea, and mucositis as frequent treatment-related AEs (14). In-class toxicities for pictilisib, another pan-class PI3K inhibitor, included diarrhea, hyperglycemia, rash, and pneumonitis (15). Colitis observed with taselisib is similar to ...
http://cancerdiscovery.aacrjournals.org/content/7/7/704?ijkey=gKQ0Qx5D7qje6&keytype=ref&siteid=aacrjnls&utm_source=abstract&utm_medium=landingpage21&utm_campaign=CDclin
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell...  Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell...
Background. The addition of cyclo-oxygenase-2 (COX-2) inhibitors and prolonged constant infusion (PCI) of gemcitabine to treatment for advanced non-small-cell lung cancer (NSCLC) might improve treatment efficacy. We aimed to assess whether the addition of rofecoxib or PCI gemcitabine could improve overall survival compared with first-line treatment with cisplatin plus gemcitabine given by standard infusion. Methods. Patients with stage IV or IIIb (with supraclavicular nodes or pleural effusion) NSCLC who were under 70 years of age and who had performance status 0 or 1 were eligible for this multicentre, prospective, open-label, randomised phase III trial with 2×2 factorial design. Patients were randomly assigned to one of four treatment groups: group A,gemcitabine 1200 mg/m2 in a 30-min intravenous infusion on days 1 and 8 and intravenous cisplatin 80 mg/m2 on day 1, every 21 days for six cycles; group B, the same treatments as group A plus oral rofecoxib 50 mg/day until disease progression; ...
https://iris.unicampania.it/handle/11591/185581
Docetaxel in Combination With Doxorubicin: A Phase I Dose-Finding Study | Cancer Network | The Oncology Journal  Docetaxel in Combination With Doxorubicin: A Phase I Dose-Finding Study | Cancer Network | The Oncology Journal
This phase I dose-finding study examined the effects of the combination of doxorubicin and docetaxel (Taxotere) in 42 women with metastatic breast cancer. The combination was studied at six different dosing levels. The maximum tolerated doses were defined as doxorubicin, 50 mg/m², and docetaxel, 85 mg/m², with sepsis as the dose-limiting toxicity. 1
http://www.cancernetwork.com/review-article/docetaxel-combination-doxorubicin-phase-i-dose-finding-study
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME...  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME...
BACKGROUND: The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC). METHODS: Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression. Investigators and patients were masked to assignment. The primary endpoint was progression-free survival (PFS) by independent central review, analysed by intention to treat after 714 events in all patients. The key secondary endpoint was overall survival, analysed by ...
http://www.forskningsdatabasen.dk/catalog/259602125
Prednisone 10mg Dosage Schedule : Huge Savings  Prednisone 10mg Dosage Schedule : Huge Savings
Highest Independently Rated Canadian Online Pharmacy. Prednisone 10mg Dosage Schedule. Browse An Extensive Online Catalogue Of Health Products And Medicines. Save On Discount Prescription Drugs From Canada.
http://murraywholesale.com/beverages.html?dir=asc&limit=5&mode=list&order=price&p=23
Dosage Schedule | NEXIUM® (esomeprazole magnesium) Packets  Dosage Schedule | NEXIUM® (esomeprazole magnesium) Packets
Recommended dosage schedule information for NEXIUM® (esomeprazole magnesium) Packets in the treatment of GERD and related conditions, such as erosive esophagitis.
https://www.nexiumpackets.com/hcp/dosage-administration/nexium-packets-dosage-schedule.html
Institute of Cancer Research Repository - A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid...  Institute of Cancer Research Repository - A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid...
Purpose: Ridaforolimus is an investigational, potent, selective mTOR inhibitor. This study was conducted to determine the recommended phase 2 dose (RP2D), maximum tolerated dose, safety, pharmacokinetics, and antitumor activity of oral ridaforolimus in children with advanced solid tumors. Experimental Design: In this phase 1, multicenter, open-label study in children aged 6 to , 18 years with advanced solid tumors, ridaforolimus was administered orally for 5 consecutive days/week in 28-day cycles until progression, unacceptable toxicity, or consent withdrawal. Dose started at 22 mg/m(2) and increased to 28 mg/m(2) and 33 mg/m(2), followed by expansion at the RP2D. Results: Twenty patients were treated; 18 were evaluable for dose-limiting toxicities. One dose-limiting toxicity (grade 3 increased alanine aminotransferase) occurred in 1 patient at 33 mg/m(2). Dose escalation concluded at 33 mg/m(2); the maximum tolerated dose was not determined. The most common treatmentrelated adverse events ...
http://publications.icr.ac.uk/15672/
Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung...  Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung...
Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
http://libros.duhnnae.com/2017/jul2/149890194579-Combination-chemotherapy-with-intermittent-erlotinib-and-pemetrexed-for-pretreated-patients-with-advanced-non-small-cell-lung-cancer-a-phase-I-dose-f.php
Phase I Dose-Escalation Study of Brutons Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma  Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
The goal of this clinical research study is to find the highest tolerable dose of PCI-32765 that can be given to patients with recurrent B-cell lymphoma.
https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2008-0494.html
Appeals court: 1 Texas execution back on schedule - AP News - Breaking News  Appeals court: 1 Texas execution back on schedule - AP News - Breaking News
Appeals court: 1 Texas execution back on schedule - AP News: HOUSTON (AP) - A federal appeals court on Wednesday threw .01/18/2018 3:18:36AM EST.
https://townhall.com/news/politics-elections/2014/04/02/texas-pushes-to-keep-execution-drug-source-secret-n1817824
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study | Archivio della...  Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study | Archivio della...
This trial was conducted to assess the activity and tolerability of the gemcitabine, epirubicin, taxol triplet combination in patients with operable breast cancer. After core biopsy, 43 women with stage II-IIIA breast cancer were treated with gemcitabine 1000 mg m(-2) over 30 min on days 1 and 4, epirubicin 90 mg m(-2) as an intravenous bolus on day 1, and taxol 175 mg m(-2) as a 3-h infusion on day 1, every 21 days for four cycles. The primary end point was the percentage of pathological complete responses (pCR) in the breast; secondary end points were tolerability, clinical response rates, overall and progression-free survival, tumour biomarkers before and after primary chemotherapy (PCT). All patients were included in safety and survival analyses; 41 eligible patients were evaluated for response. The overall clinical response rate was 87.8% (95% CI 77.8 - 97.8), with 26.8% complete responses ( 95% CI 13.3 - 40.3). A pCR in the breast was observed in six patients (14.6%; 95% CI 3.8 - 25.4); 15 ...
https://iris.unimore.it/handle/11380/304284
HKU Scholars Hub: A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic...  HKU Scholars Hub: A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic...
The objective of the present study is to investigate the clinical efficacy and tolerance of vinorelbine and pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC) with prior taxane and/or anthracycline treatment. A total of 25 patients who previously received taxane- and/or anthracycline-based chemotherapy as first- and/or second-line treatment of MBC were entered into the study and were treated with 20 mg/m2 vinorelbine on day 1 and 8 and 30 mg/m2 PLD on day 1 every 3 weeks. All were evaluated for efficacy, quality of life, and tolerance. Three complete and 6 partial responses were observed in 25 patients for an objective response rate of 36% (95% confidence interval: 17-55%). Eight patients (32%) had stable disease of not less than 3 months and 8 patients (32%) had disease progression. The median progression-free survival was 6.7 months (range, 2-18 months), and the median overall survival was 13.2 months (range, 3-31 months). Severe toxicities (grade 3 or above) ...
http://hub.hku.hk/handle/10722/192067
Plus it  Plus it
Purpose: This phase I study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the combination of decitabine with vorinostat.. Patients and Methods: Patients with advanced solid tumors or non-Hodgkins lymphomas were eligible. Sequential and concurrent schedules were studied.. Results: Forty-three patients were studied in 9 different dose levels (6 sequential and 3 concurrent). The maximum tolerated dose (MTD) on the sequential schedule was decitabine 10 mg/m2/day on days 1 to 5 and vorinostat 200 mg three times a day on days 6 to 12. The MTD on the concurrent schedule was decitabine 10 mg/m2/day on days 1 to 5 with vorinostat 200 mg twice a day on days 3 to 9. However, the sequential schedule of decitabine 10 mg/m2/day on days 1 to 5 and vorinostat 200 mg twice a day on days 6 to 12 was more deliverable than both MTDs with fewer delays on repeated dosing and it represents the recommended phase II (RP2D) dose of this combination. Dose-limiting toxicities during the ...
http://clincancerres.aacrjournals.org/content/early/2011/03/04/1078-0432.CCR-10-1893
Continuous administration of cefotaxime at exacerbation of COPD | Thorax  Continuous administration of cefotaxime at exacerbation of COPD | Thorax
This randomised prospective non-blinded study compared the pharmacokinetics, pharmacodynamics, antibiotic resistance and clinical efficacy of continuous vs intermittent administration of cefotaxime in 93 patients with chronic obstructive pulmonary disease (COPD) requiring hospitalisation for moderate to severe community acquired exacerbations (GOLD stages 2-4). Forty-seven patients received 2 g of cefotaxime as a continuous infusion over 24 h plus a loading dose of 1 g, while 46 patients received the drug intermittently (1 g three times daily). The mean duration of treatment was 10 days.. The most commonly isolated pathogens were Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Clinical cure was achieved in 37/40 (93%) with continuous infusion and 40/43 (93%) with intermittent administration (p = 0.93). No patients in the continuous group had antibiotic concentrations lower than minimal inhibitory concentration (MIC) compared with 40% in the intermittent group. Samples ...
http://thorax.bmj.com/content/62/5/461
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As 1st-Line Chemo - Ovarian...  Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As 1st-Line Chemo - Ovarian...
Patients and Methods Six hundred sixty-seven patients with stage I to IV CCC of the ovary were randomly assigned to receive irinotecan 60 mg/m2 on days 1, 8, and 15 plus cisplatin 60 mg/m2 on day 1 (CPT-P group) every 4 weeks for six cycles or paclitaxel 175 mg/m2 plus carboplatin area under the curve 6.0 mg/mL/min on day 1 every 3 weeks for six cycles (TC group). The primary end point was progression-free survival. Secondary end points were overall survival, overall response rate, and adverse events ...
https://ovariancancerandus.blogspot.com/2016/07/randomized-phase-iii-trial-of.html
Docetaxel (Taxotere) in the Treatment of Non-Small Cell Lung Canc...: Ingenta Connect  Docetaxel (Taxotere) in the Treatment of Non-Small Cell Lung Canc...: Ingenta Connect
Preclinical and phase II studies revealed that docetaxel is active against NSCLC. In chemotherapy-naïve patients with NSCLC response rates ranged from 19% to 54% with a median duration of survival ranging from 6.3 months to 11 months, and 1-year survival ranging from 21% to 71%. Docetaxel as single agent provided a survival as well as a clinical benefit over BSC in untreated patients with NSCLC. Docetaxel has been efficiently combined with cisplatin (ORR 33%-46%), carboplatin (ORR 30%-48%), vinorelbine (ORR 20%-51%), gemcitabine (ORR 37%-47%), with a median survival ranging from 5-14 months. A preliminary analysis of a multicenter randomized trial comparing docetaxel / CDDP with docetaxel / gemcitabine revealed that the two regimens had comparable activity in terms, of response rates, duration of response, TTP and overall survival; however, the docetaxel / gemcitabine combination has a most favourable toxicity profile compared to docetaxel / CDDP ...
http://www.ingentaconnect.com/content/ben/cmc/2002/00000009/00000008/art00006
Pentagons Top Weapons Tester: F-35 Still Challenged | Ares  Pentagon's Top Weapons Tester: F-35 Still Challenged | Ares
Volume 1" (2011).. rand.org/content/dam/rand/pubs/monographs/2011/RAND_MG1171.1.pdf. Table 4.3 (page 43) shows that in the 2001 SAR the USAF IOC was to be June 2011, and the 2009 SAR placed that date at March 2013. By May 2013 the USAF predicting an IOC by December 2016. This of course is, we are to believe, "on schedule.". Table 4.9 on page 56 shows just how badly production was slipped between the 2001 plan and 2011, causing at that time production to not end in 2027 as planned in 2001. Rather production was to extend into 2034 in the 2009 scheme. If we all play pretend that may be "on schedule." If we pretend hard enough it might actually end in 2034. Try to wish real hard, it may save Tinkerbell.. Once again the program is NOT on schedule, it is on a schedule contrived by use of an imaginary start date, one selected to fit the claim being made. Further slippages will be met, as they have in the past, by newly invented start dates. 2001? It never happened, the world was created in 2013. Or ...
http://aviationweek.com/blog/pentagons-top-weapons-tester-f-35-still-challenged?page=1
M1 Central Nervous System/ Head & Neck- 2009 Daily Schedule  M1 Central Nervous System/ Head & Neck- 2009 Daily Schedule
The neuroscience sequence is foundational in nature and stresses the organizational principles and structure/function relationships in the central ner
https://www.merlot.org/merlot/viewMaterial.htm?id=681441
Determination of renal handling of marbofloxacin in Lohi sheep (Ovis aries) following a single intravenous administration  Determination of renal handling of marbofloxacin in Lohi sheep (Ovis aries) following a single intravenous administration
The objective of present study was to investigate renal clearance, urinary excretion and underlying excretory mechanism of marbofloxacin in Lohi sheep. For this purpose, marbofloxacin was administered intravenously (IV) as single bolus dose (2.5 mg/kg body weight) to eight healthy sheep of Lohi breed. After start of experiment, blood and urine samples were drawn at predetermined time intervals and marbofloxacin concentrations in the samples were measured by reverse phase high performance liquid chromatography (RP-HPLC) using UV/Vis detector. The mean ± SD values of creatinine in plasma and urine were 15.37 ± 0.65 µg/ml and 246.7 ± 48.05 µg/ml, respectively. Glomerular filtration rate was 1.29 ± 0.22 ml/min/kg whereas urinary flow rate was observed to be 0.084 ± 0.016 ml/min/kg. The renal clearance of marbofloxacin in Lohi sheep was 9.45 ± 2.12 ml/min/kg. Cumulative percentage dose excreted was seen to be maximum at 24 h post drug administration. It was concluded that renal handling of
http://ijvr.shirazu.ac.ir/article_4030_691.html
Emergency superficial temporal artery to middle cerebral artery bypass after intravenous recombinant tissue plasminogen...  Emergency superficial temporal artery to middle cerebral artery bypass after intravenous recombinant tissue plasminogen...
Emergency superficial temporal artery to middle cerebral artery bypass after intravenous recombinant tissue plasminogen activator administration for acute cerebral ischemia in a patient with moyamoya disease. - Sadaharu Tabuchi, Sadao Nakajima, Yutaka Suto, Hiroyuki Nakayasu
http://www.curehunter.com/public/pubmed24516411.do
Vectibix (Panitumumab Injection for Intravenous Use): Side Effects, Interactions, Warning, Dosage & Uses  Vectibix (Panitumumab Injection for Intravenous Use): Side Effects, Interactions, Warning, Dosage & Uses
Learn about Vectibix (Panitumumab Injection for Intravenous Use) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
https://www.rxlist.com/vectibix-drug.htm
British Library EThOS: Afferent visual pathway assessment in an exploratory trial of autologous mesenchymal stem cells in...  British Library EThOS: Afferent visual pathway assessment in an exploratory trial of autologous mesenchymal stem cells in...
There is a considerable need for treatments in MS for preventing progressive neurological disability. Assessment of the afferent visual pathway shows potential in investigating new therapies in MS. Mesenchymal Stem Cells exhibit properties of potential therapeutic relevance in progressive MS. A phase I/IIA trial of adult autologous mesenchymal stem cells as a potential therapy for Multiple Sclerosis [MSCIMS] was designed as an open label, pre (up to 20 months) vs. post treatment (up to 10 months) (single intravenous administration of autologous bone marrow derived mesenchymal stem cells) comparison study in ten secondary progressive MS patients. Primary end points were adverse events and secondary end points were efficacy measures. All 10 patients had previous history of clinical optic neuritis: this was in order to enable longitudinal structural and functional assessments of the disease-affected afferent visual pathway. Piecewise linear mixed models were used to assess the change in gradients ...
http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.594361
Intravenous Delivery of Clot-busting Drug Still Best Intervention for Ischemic Stroke ( Intravenous delivery of an approved clo...  Intravenous Delivery of Clot-busting Drug Still Best Intervention for Ischemic Stroke ( Intravenous delivery of an approved clo...
Health,Intravenous delivery of an approved clot-busting drug remains the most... The Guidelines for the Early Management of Adults with Ischemic S... The guidelines focus on the crucial first hours from the time an ... The panel emphasized the importance of public education on the sy... ? Sudden numbness or weakness of the face arm or leg especially...,Intravenous,Delivery,of,Clot-busting,Drug,Still,Best,Intervention,for,Ischemic,Stroke,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
http://www.bio-medicine.org/medicine-news/Intravenous-Delivery-of-Clot-busting-Drug-Still-Best-Intervention-for-Ischemic-Stroke-19881-1/
Report of research results:Development of a novel therapy for treating acute liver failure using M2 macrophages inducers...  Report of research results:Development of a novel therapy for treating acute liver failure using M2 macrophages inducers...
ALF induced by various causes (e.g. drugs, hepatitis viruses, autoimmune hepatitis) is unfavorable and intractable liver disease that is characterized by massive hepatocyte destruction and an uncontrolled inflammatory response. Although there are some supportive treatments, such as blood purification, liver transplantation is currently the only available treatment in progressive liver failure. However, its application is limited due to the shortage of donors and exorbitant cost. Therefore, alternative treatments for patients with ALF are urgently needed. We previously reported that a single intravenous administration of the conditioned medium of SHED (SHED-CM) improved rat ALF model without the cell-transplantation. However, it was unclear which among the various factors derived from SHED are responsible for ALF recovery. Here, we investigated the therapeutic activity of MCP-1/sSiglec-9, a major component of SHED-CM, in rat ALF model.. ...
http://www.tokushima-u.ac.jp/english/docs/2017030900062/
DWI-ASPECTS as a Predictor of Dramatic Recovery After Intravenous Recombinant Tissue Plasminogen Activator Administration in...  DWI-ASPECTS as a Predictor of Dramatic Recovery After Intravenous Recombinant Tissue Plasminogen Activator Administration in...
DWI-ASPECTS ≥7 was an independent predictor of short-term neurological recovery after an M1-MCAO. Limited DWI changes before IV-tPA have been reported as a predictor of neurological recovery.4 Presence of a clinical-DWI mismatch defined as DWI-ASPECTS ≥7 and an NIHSS score ≥8 has also been reported to be predictors of neurological recovery after IV-tPA.5 An advantage of our study is that the utility of DWI-ASPECTS was evaluated after adjusting for several established imaging and laboratory parameters.. Although early recanalization was associated with DR in patients with DWI-ASPECTS ≥7 and ,7, its role regarding clinical and radiological outcomes depended on the initial DWI-ASPECTS. In patients with DWI-ASPECTS ≥7, the favorable outcome rate and follow-up infarct volume were not statistically different between patients with and without early recanalization. To the contrary, in patients with DWI-ASPECTS ,7, favorable outcomes were only seen in patients with early recanalization. Early ...
http://stroke.ahajournals.org/content/44/2/534.long
Search Articles | University of Toronto Libraries  Search Articles | University of Toronto Libraries
We examined drug concentrations and the incidence of retinal degeneration in the eyes of albino BALB/c mice after a single intravenous administration of ...
https://query.library.utoronto.ca/index.php/search/q?kw=SubjectTerms:Sitafloxacin
Diflucan injection package insert - How long do you take diflucan for yeast infection  Diflucan injection package insert - How long do you take diflucan for yeast infection
Fluconazole is a white crystalline solid which is slightly soluble in water and saline.Dihydroergotamine Injection and Nasal Spray: learn about side effects, dosage, special precautions, and more on MedlinePlus.. When administered intravenously, VELCADE is administered as a 3 to 5 second bolus intravenous injection.DIFLUCAN by intravenous injection is compatible with the administration of the following liquids: a).. TODAY OFFER: Only 0.75 per pill. is diflucan 50 mg good for ringworm treatment, buy diflucan online ...
http://settimocieloshop.info/lica/diflucan-injection-package-insert-2348.php
Ceramide-Specific Glycosyltransferase | Akt Inhibitor A-443654 Interferes with Mitotic Progression  Ceramide-Specific Glycosyltransferase | Akt Inhibitor A-443654 Interferes with Mitotic Progression
Purpose Glial-derived neurotrophic factor (GDNF) is definitely a potential therapy for stroke, Parkinsons disease, or drug addiction. high clearance rates of 8C10?mL/kg/min. Conclusions A no-observable-adverse-effect level is established in the Rhesus monkey for the acute administration of the HIRMAb-GDNF fusion protein. The fusion protein targeting the insulin receptor has a PK profile similar to a classical small molecule. and were approved by the Institutional Animal Care and Use Committee. Study Design Dose Selection The animals were treated with either 0, 0.4, 2, or 10?mg/kg of the HIRMAb-GDNF fusion protein administered as a slow bolus intravenous injection over a 2-min period. In the 2-week toxicity study, the doses were Rabbit Polyclonal to CDK1/CDC2 (phospho-Thr14). administered every 12?h for SRT1720 HCl five consecutive doses over a 60-hr period, with a total dosing of 0, 2, 10, and 50?mg/kg. 2-Week Toxicity Study The initial clinical application of the HIRMAb-GDNF fusion protein is ...
http://a-443654.com/category/ceramide-specific-glycosyltransferase/
Ouabain is not detectable in human plasma. | Hypertension  Ouabain is not detectable in human plasma. | Hypertension
An enzyme-linked immunosorbent assay is described for the measurement of ouabain in human plasma. This assay is specific for ouabain, strophanthidin, and ouabagenin, with other steroids, including digoxin and vasopressor hormones, exhibiting negligible cross-reactivity. Assay sensitivity was 0.06 nmol/L if 1 mL plasma was extracted and less than 0.005 nmol/L when 20 mL plasma was analyzed. Extracted plasma samples showed ouabainlike immunoreactivity that diluted in parallel with the ouabain standard curve. Repeated extraction and assay of single plasma samples, however, did not produce consistent results in the assay. Increased specificity was obtained by high-performance liquid chromatography of sample extracts before assay. When high-performance liquid chromatographic profiles of plasma spiked with ouabain standard or following bolus intravenous injections of ouabain into normal human volunteers were compared with profiles of unspiked plasma, there was no support for the immunoreactive ...
http://hyper.ahajournals.org/content/24/5/549
Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for...  Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for...
Welcome to CDC stacks | Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic...  Welcome to CDC stacks | Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic...
Among 7193 patients treated with intravenous tissue plasminogen activator, 516 (7·2%) died during hospitalization. Factors associated with in-hospital death were older age, male gender, National Institutes of Health Stroke Scale score, history of myocardial infarction or coronary artery disease, and history of nonvalvular atrial fibrillation. Increasing age, higher National Institutes of Health Stroke Scale score, and history of dyslipidemia were associated with symptomatic intracerebral hemorrhage. There was no difference in the rates of in-hospital death or symptomatic intracerebral hemorrhage among patients treated with intravenous tissue plasminogen activator within three-hours of time last known to be well and those treated between three and 4·5 hours after this time ...
https://stacks.cdc.gov/view/cdc/31394
Clinical Pharmacology of the Dietary Supplement Creatine Monohydrate | Pharmacological Reviews  Clinical Pharmacology of the Dietary Supplement Creatine Monohydrate | Pharmacological Reviews
To date, much of the work on Cr has focused on the pharmacological effects rather than on characterizing the pharmacokinetics. Of the studies that examined the behavior of Cr in blood, none have truly characterized the pharmacokinetics except forC max andT max thus leaving a gap in the research. Despite the lack of pharmacokinetic interpretation, these studies can serve as a basis for future work on Cr pharmacokinetics.. To truly understand the pharmacokinetics of Cr, data are needed after an intravenous bolus dose. Although some studies have administered Cr as an intravenous infusion in humans (Crim et al., 1976) there is only one available intravenous bolus study from Fitch and Sinton (1964). Small amounts of 14C-Cr (2-60 μCi or 0.1-3 mg) were given as an intravenous bolus to five patients with various muscular disorders and followed over time. The half-life of14C-Cr in plasma was calculated to be 20 to 70 min. It appears the Cr follows a one-compartment body model. However, two of the five ...
http://pharmrev.aspetjournals.org/content/53/2/161.full
New Research Raises Doubts Over Safety of Intravenous Treatments  New Research Raises Doubts Over Safety of Intravenous Treatments
A serious and previously misunderstood contaminant that brings the safety and efficacy of intravenous treatments into question has been identified by German scientists.
http://www.medindia.net/news/New-Research-Raises-Doubts-Over-Safety-of-Intravenous-Treatments-57384-1.htm
Dynamic computed tomography with low- and high-molecular-mass contrast agents to assess microvascular permeability...  Dynamic computed tomography with low- and high-molecular-mass contrast agents to assess microvascular permeability...
Interstitial collagen formation and transformation of the fenestrated hepatic sinusoids into continuous capillaries are major ultrastructural changes that occur in liver cirrhosis and fibrosis. These modifications lead to progressive restriction of blood-liver exchanges. The purpose of our study was to evaluate the permeability changes in a model of hepatic fibrosis by using dynamic computed tomography (CT) enhanced with contrast agents of different molecular masses. Dynamic single-section CT of the liver was performed after intravenous bolus administration of a low-molecular-mass contrast agent (iobitridol) and an experimental high-molecular-mass agent (P840) in normal control rabbits and in rabbits with hepatic fibrosis. Hepatic, aortic and portal venous time-density curves were fitted with a dual-input one-compartmental model to calculate the hepatic mean transit time and distribution volume of the contrast agents. In the rabbits with liver fibrosis, the mean transit time of the ...
http://www.clinsci.org/content/103/2/213
EURORAD - Radiologic Teaching Files  EURORAD - Radiologic Teaching Files
In Acute Myocardial infarction, MRI is useful for identifying topography and extent of myocardial infarction . After intravenous bolus administration of contrast agent, normal myocardium shows increased signal intensity. After a recent myocardial infarction, there is a hypo-enhanced area on early (first pass perfusion acquisition) images corresponding to the affected myocardium. Delayed images demonstrate areas of hyperenhancement in the infarcted area. Cine MRI demonstates motion abnormalities of cardiac wall with poor wall motion ...
http://eurorad.org/eurorad/case.php?id=2692&lang=en
Norepinephrine Bitartrate - Vasoconstrictor Agents, Mydriatics, Bronchodilator Agents, Sympathomimetic, ATC...  Norepinephrine Bitartrate - Vasoconstrictor Agents, Mydriatics, Bronchodilator Agents, Sympathomimetic, ATC...
Epinephrine is indicated for intravenous injection in treatment of acute hypersensitivity, treatment of acute asthmatic attacks to relieve bronchospasm, and treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular heart block with syncopal seizures (Stokes-Adams Syndrome). The actions of epinephrine resemble the effects of stimulation of adrenergic nerves. To a variable degree it acts on both alpha and beta receptor sites of sympathetic effector cells. Its most prominent actions are on the beta receptors of the heart, vascular and other smooth muscle. When given by rapid intravenous injection, it produces a rapid rise in blood pressure, mainly systolic, by (1) direct stimulation of cardiac muscle which increases the strength of ventricular contraction, (2) increasing the heart rate and (3) constriction of the arterioles in the skin, mucosa and splanchnic areas of the circulation. When given by slow intravenous injection, epinephrine usually produces only a moderate ...
http://pharmacycode.com/Norepinephrine_Bitartrate.html
Plus it  Plus it
Verapamil is a calcium-channel antagonist that can reduce the strength and rate of contraction of cardiac muscle (Cohen et al., 1987; Satohet al., 1979; Raschack, 1976) and the tone of vascular smooth muscle (Nawrath and Raschack, 1987; Golenhofen and Lammel, 1972). It has been used clinically to treat hypertension, myocardial ischemia and tachyarrhythmias, the latter often by intravenous bolus administration or short infusion. Early studies of this type of administration showed a delay between the concentration of verapamil in venous blood and its effects on A-V conduction in some circumstances (McAllister and Kirsten, 1982) but not others (McAllister et al., 1977). Attempts to account for this delay (hysteresis) by measuring the myocardial concentrations of verapamil have had mixed success. In dogs, verapamil concentrations in direct myocardial biopsies were linearly related to myocardial effects, but with some suggestion of hysteresis (Keefe and Kates, 1982). In humans, the direct effects of ...
http://jpet.aspetjournals.org/content/284/3/1048
China Human Immunoglobulin (pH4) for Intravenous Injection Industry Research Report 2013  China Human Immunoglobulin (pH4) for Intravenous Injection Industry Research Report 2013
This report has firstly introduced Human Immunoglobulin (pH4) for Intravenous Injection definition classification industry chain etc related information. Then introduced Human Immunoglobulin (pH4) for Intravenous Injection manufacturing technology and product specifications, And then summary statistics China major Human Immunoglobulin (pH4) for Intravenous Injection manufacturers 2010-2016 Human Immunoglobulin (pH4) for Intravenous Injection capacity production supply demand shortage and Human Immunoglobulin (pH4) for Intravenous Injection selling price cost gross margin and production value, and also introduced China 25 manufacturers company basic information, 2010-2016 Human Immunoglobulin (pH4) for Intravenous Injection capacity production price cost gross margin production value China market share etc details information ...
http://marketresearchinsights.blogspot.com/2013/01/china-human-immunoglobulin-ph4-for_30.html
Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594  Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594
SAN FRANCISCO, July 25, 2012- Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer.
http://www.newswire.ca/fr/news-releases/jennerex-announces-first-patient-treated-in-phase-2-clinical-trial-of-intravenous-delivery-jx-594-in-patients-with-advanced-liver-cancer-510507971.html
Reversal of Haloperidol-Induced Cardiac Arrest by Using Lipid Emulsion | Annals of Internal Medicine | American College of...  Reversal of Haloperidol-Induced Cardiac Arrest by Using Lipid Emulsion | Annals of Internal Medicine | American College of...
Case Report: A 45-year-old woman came to the hospital reporting palpitations and chest pain. Her medical history included untreated hypertension, anxiety, depression, opioid abuse, and cigarette smoking. She was extremely agitated. Her heart rate was 64 beats/min, respiratory rate was 30 breaths/min, and blood pressure was 145/59 mm Hg. Physical examination was within normal limits, and toxicology screening was positive for cannabis. The electrocardiogram showed sinus rhythm, left atrial enlargement, Q waves in V1 and V2, diffuse T-wave abnormalities, QT interval of 508 ms, and corrected QT interval of 545 ms. Sublingual nitroglycerin, intravenous ketorolac, morphine, and nalbuphine were given but did not relieve her symptoms. She was given haloperidol, 5 mg, by rapid intravenous injection for her agitation, and within minutes, she developed ventricular bigeminy followed by pulseless, multiform ventricular tachycardia (Figure). Cardiopulmonary resuscitation was initiated, and the patient ...
http://annals.org/aim/article/744516/reversal-haloperidol-induced-cardiac-arrest-using-lipid-emulsion
most circumstances, granisetron iv administration anal sphincters  most circumstances, granisetron iv administration anal sphincters
PIPERAZINE-META TRIFLUOROMETHYLTHIORIBOSE-5 h. Am J Psychiatry 1997;154(9)1248в54. Serradeil-Le Gal that multiple receptor types (the granisetron iv administration Y1, Y2, Y3, PP1 or Y4, PYY-preferring and appetite receptors) support granisetron iv administration diverse actions of NPY and those of the two closely related hormones, peptide YY (PYY) and pancreatic polypeptides (PP) (Tatemoto et aL, 1982). 123 Introduction .
http://design-citi.ru/best-pills-in-india/granisetron-iv-administration.html
Pausera 500 (MG) Tablets - 10 Tabs - Medi Tree India  Pausera 500 (MG) Tablets - 10 Tabs - Medi Tree India
Ingredients: Tranexamic Acid 500 mg. Packing: 10 Tabs/Strip. Dosage: As directed by the physician.. Precautions: Mild to moderate renal impairment, irregular menstrual bleeding, previous history of thromboembolic disease, haematuria, monitor closely in disseminated intravascular coagulation, monitor liver function tests (LFTs or LFs), eye examination regularly during long-term use, discontinue if disturbance in colour vision occurs, avoid intravenous (IV) injection rate ,1 ml/minute due to risk of hypotension, pregnancy, lactation.. Contraindications: Severe renal failure, active intravascular clotting, thromboembolic disease, colour vision disorders, subarachnoid bleeding.. Side Effects: Diarrhoea, nausea, vomiting, disturbances in colour vision, giddiness, hypotension (after rapid intravenous injection), thromboembolic events.. Storage Conditions: Store it at room temperature and in an airtight container. Keep away from light and children.. ...
http://retail.meditreeindia.com/product/pausera-500-mg-tablets-10-tabs/
What is a good antibiotic for cellulitis following iv? - Answered by top doctors on HealthTap  What is a good antibiotic for cellulitis following iv? - Answered by top doctors on HealthTap
Dr. Maes responded: Sensitivites. Hopefully, if you were sick enough to need IV antibiotics, cultures were done to see which specific |a href="/topics/bacteria" track_data="{
https://www.healthtap.com/user_questions/92970-what-is-a-good-antibiotic-for-cellulitis-following-iv
Results of the MRI substudy of the intravenous magnesium efficacy in stroke trial | ScholarBank@NUS  Results of the MRI substudy of the intravenous magnesium efficacy in stroke trial | [email protected]
Background and Purpose-: Although magnesium is neuroprotective in animal stroke models, no clinical benefit was confirmed in the Intravenous Magnesium Efficacy in Stroke (IMAGES) trial of acute stroke patients. The Magnetic Resonance in IMAGES (MR IMAGES) substudy investigated the effects of magnesium on the imaging surrogate outcome of infarct growth. Methods-: IMAGES trial patients in participating centers were randomized to receive either intravenous magnesium or placebo within 12 hours of stroke onset. Infarct growth was defined as volume difference between baseline diffusion-weighted imaging and day 90 fluid-attenuated inversion recovery image lesions. Patients who died were imputed the largest infarct growth observed. Results-: Among the 90 patients included in the primary analysis, there was no difference in infarct growth (median absolute growth, P=0.639; median percentage growth, P=0.616; proportion with any growth, P=0.212) between the 46 treated with magnesium and 44 with placebo. ...
http://scholarbank.nus.edu.sg/handle/10635/130086
Bioavailability - Wikipedia  Bioavailability - Wikipedia
Therefore, a drug given by the intravenous route will have an absolute bioavailability of 100% (f = 1), whereas drugs given by other routes usually have an absolute bioavailability of less than one. If we compare the two different dosage forms having same active ingredients and compare the two drug bioavailability is called comparative bioavailability.. Although knowing the true extent of systemic absorption (referred to as absolute bioavailability) is clearly useful, in practice it is not determined as frequently as one may think. The reason for this is that its assessment requires an intravenous reference, that is, a route of administration that guarantees that all of the administered drug reaches the systemic circulation. Such studies come at considerable cost, not least of which is the necessity to conduct preclinical toxicity tests to ensure adequate safety, as well as there being potential problems due to solubility limitations. These limitations may be overcome, however, by administering ...
https://en.wikipedia.org/wiki/Bio-availability
Duration of intravenous antibiotic therapy in people with cystic fibrosis  Duration of intravenous antibiotic therapy in people with cystic fibrosis
Plummer A, Wildman M, Gleeson T. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2016, Issue 9. Art. No.: CD006682. DOI: 10.1002/14651858.CD006682.pub5 ...
https://www.ecfs.eu/print/7015
INTRAVENOUS MAGNESIUM FOR TREATING ACUTE EXACERBATIONS OF ASTHMA IN CHILDREN: A SYSTEMATIC REVIEW | SUPPLEMENT TO PEDIATRICS |...  INTRAVENOUS MAGNESIUM FOR TREATING ACUTE EXACERBATIONS OF ASTHMA IN CHILDREN: A SYSTEMATIC REVIEW | SUPPLEMENT TO PEDIATRICS |...
INTRODUCTION: Inhaled bronchodilators and systemic corticosteroids are the mainstay of treatment for acute exacerbations of asthma. A systematic review of the use of magnesium has been published, but the results are incomplete and the recommendation is "weak.". OBJECTIVE: The objective of this study was to determine the effect of intravenous magnesium in children with acute asthma.. METHODS: Randomized, controlled trials were identified by searching the Cochrane, Medline, Embase, CINAHL, and ProQuest databases. Other sources were used to identify "gray literature." Randomized, controlled trials in which children with an acute exacerbation of asthma were treated with intravenous magnesium versus placebo were included. Data were extracted from the full papers, and methodologic quality was assessed using a scale from 0 to 5.. RESULTS: Six studies involving 215 patients were included. Hospital stay was reduced in the magnesium-treated group. The percentage improvement in the percentage predicted ...
http://pediatrics.aappublications.org/content/121/Supplement_2/S159.1
Cost utility analysis of intravenous tissue plasminogen activator in acute ischemic stroke in Canada - Oxford Neuroscience  Cost utility analysis of intravenous tissue plasminogen activator in acute ischemic stroke in Canada - Oxford Neuroscience
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
https://www.neuroscience.ox.ac.uk/publications/84624
Plus it  Plus it
Despite the successful identification of cases in which vessels were directly visualized at the same time as epidural contrast in our study, we recognize that the cross-sectional nature of CT may impose some limitations as well. For example, purely intravascular injections into vessels that run in the craniocaudal direction (and therefore outside the axial scan plane) would typically be recognized with CTF by the absence of epidural contrast after injection, even if the vessel is not directly seen. However, when simultaneous epidural and intravascular injection occurs involving a vessel oriented in the craniocaudal direction, it is relatively more difficult to recognize, and these injections could potentially be missed in some cases. Nevertheless, our data suggest that the overall rate for detecting intravascular injections, including those that occur concurrently with epidural injections, is not degraded to a major extent by this potential scenario.. Our investigation indicates that attention ...
http://www.ajnr.org/content/36/5/1000
Intravenous clonidine does not promote hypoxemia or platelet aggregation in man. | DIAL.pr - BOREAL  Intravenous clonidine does not promote hypoxemia or platelet aggregation in man. | DIAL.pr - BOREAL
This study was designed to evaluate hypoxemia and platelet aggregation in man following intravenous administration of clonidine. With Institutional approval and following informed consent, 20 patients (ASA I-II) without spontaneous or drug-induced coagulation disorder undergoing elective total hip replacement were studied. They were randomly divided into two groups. Group A (n = 10) received an IV loading dose of 4 micrograms/kg of clonidine in 30 minutes followed by an infusion of 1 microgram/kg/h till the end of the procedure. Group B (n = 10) received saline. Platelet aggregation was assessed before infusion and at the end of both the loading dose and the infusion. PaO2 was measured before anesthesia (FIO2 = 0.21), before femoral cementation (FIO2 = 0.40), 2 min. after prosthesis implantation (FIO2 = 1), before the end of the procedure (FIO2 = 0.40) and in the recovery room (spontaneous breathing with FIO2 = 0.21). Plasma clonidine levels were assessed at the end of both the loading dose and ...
https://dial.uclouvain.be/pr/boreal/object/boreal:13598
Dufès, Christine<...  Dufès, Christine<...
Karim, Reatul and Somani, Sukrut and Al Robaian, Majed and Mullin, Margaret and Amor, Rumelo and McConnell, Gail and Dufès, Christine (2017) Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol. Journal of Controlled Release, 246. pp. 79-87. ISSN 0168-3659 Somani, Sukrut and Robb, Gillian and Pickard, Benjamin S. and Dufes, Christine (2015) Enhanced gene expression in the brain following intravenous administration of lactoferrin-bearing polypropylenimine dendriplex. Journal of Controlled Release, 217. pp. 235-242. ISSN 0168-3659 Lim, Li Ying and Koh, Pei Yin and Somani, Sukrut and Al Robaian, Majed and Karim, Reatul and Yean, Yi Lyn and Mitchell, Jennifer and Tate, Rothwelle J. and Edrada-Ebel, RuAngelie and Blatchford, David R. and Mullin, Margaret and Dufès, Christine (2015) Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes. Nanomedicine: Nanotechnology, Biology and Medicine, ...
https://strathprints.strath.ac.uk/view/author/134081.html
Clinical Trials Registry | Internet Stroke Center  Clinical Trials Registry | Internet Stroke Center
This pilot trial will be the first step toward direct comparison of delivery of endovascular reperfusion therapy to intravenous recombinant tissue plasminogen activator (rt-PA) in a time-to-treatment framework shown as most effective by the NINDS rt-PA Stroke Trial. A randomized trial is justified for the following reasons: 1) The high rate of death and disability associated with ischemic stroke despite treatment with intravenous rt-PA mandates critical analysis of alternate therapies with therapeutic potential, 2) endovascular treatment for acute ischemic stroke is expanding in North America without compelling evidence of safety and efficacy from well-designed clinical trials, 3) critical cost-effectiveness analysis cannot be done without acquiring pertinent outcomes data from controlled studies. Trial Stopped: Poor recruitment ...
http://www.strokecenter.org/trials/clinicalstudies/feasibility-study-of-iv-recombinant-tissue-plasminogen-activator-rtpa-vs-primary-endovascular-therapy-for-acute-ischemic-stroke/description
Intravenous gene therapy protects normal tissue of mice during whole-body radiation  Intravenous gene therapy protects normal tissue of mice during whole-body radiation
In this study, we found that the same therapy administered intravenously also offers protection during exposure to whole-body irradiation." Dr. Greenberger added that intravenous administration could potentially offer wide-reaching protection to the public in the event of a terrorist attack since experts believe a significant number of the population would die within 30 days of receiving a large dose of radiation to the entire body.. In the study, mice were used to test the protective effects of manganese superoxide dismutase plasmid liposome (MnSOD-PL) gene therapy on the bone marrow during whole-body irradiation. The researchers found that in a control group of mice that received an initial 9 Gy dose of radiation there was 80 percent survival at 30 days compared to 93.3 percent survival during the same length of time for an experimental group of mice that were injected with MnSOD-PL prior to irradiation. As the level of radiation exposure was increased, survival rates in the mice injected with ...
http://www.innovations-report.com/html/reports/medicine-health/report-73665.html
Plus it  Plus it
The clinical pharmacokinetics of etoposide were studied in eight pediatric patients with refractory solid tumors. The α-phase half-life, β-phase half-life, volume of distribution, and elimination rate constant averaged 0.82 hr, 6.5 hr, 4.0 liters/sq m, and 0.25 hr-1, respectively. Noncompartmental parameters such as systemic clearance, mean residence time, and volume of distribution at steady-state averaged 20.9 ml/min/sq m, 7.8 hr, and 7.2 liters/sq m, respectively. A significant relationship between serum glutamic pyruvic transaminase and systemic clearance was observed, with patients having elevated serum glutamic pyruvic transaminase showing slower systemic clearance of etoposide. Systemic clearance, mean residence time, and β-phase half-life of etoposide were significantly lower in those patients who had received cisplatin prior to their Phase II etoposide trial. The average pharmacokinetic values derived from these eight pediatric patients with solid tumors did not differ significantly ...
http://cancerres.aacrjournals.org/content/44/7/3109
Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial | European Respiratory...  Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial | European Respiratory...
Magnesium sulfate has been shown to be an effective treatment in older children with asthma exacerbations, but it has not been investigated in acute severe virus-induced wheezing in young children.. The study enrolled 61 children aged 6 months to 4 years. Inclusion criteria were severe wheezing, classified as a score of ≥6 points as assessed by the Respiratory Distress Assessment Instrument (RDAI) after initial treatment with salbutamol, and the symptoms of acute viral infection. The children were randomly allocated to receive either an infusion of magnesium sulfate (40 mg·kg−1) or 0.9% sodium chloride as a placebo infusion for 20 min. Primary outcome measure was mean change in RDAI scores from baseline to 6 h after the treatment.. Change in the severity of wheezing from baseline to 6 h after the treatment, as measured by mean±sd RDAI scores, was 4.7±2.6 in the magnesium sulfate group and 4.2±4.2 in the placebo group (difference 0.5, 95% CI −1.3 to 2.3, p=0.594).. Intravenous magnesium ...
http://erj.ersjournals.com/content/51/2/1701579.long
Noradrenergic function in panic disorder. Effects of intravenous clonidine pretreatment on lactate induced panic.  Noradrenergic function in panic disorder. Effects of intravenous clonidine pretreatment on lactate induced panic.
To assess the role of noradrenergic stimulation during lactate-induced panic, ten patients with panic disorder who panicked during a standard sodium-lactate infusion underwent a repeat infusion following intravenous clonidine pretreatment. Although c
http://www.biomedsearch.com/nih/Noradrenergic-function-in-panic-disorder/1737075.html
Safety of Magnetic Resonance Contrast Media  Safety of Magnetic Resonance Contrast Media
Summary:Intravenous contrast media, specifically the gadolinium chelates, are well accepted for use in the clinical practice of magnetic resonance imaging. The gadolinium chelates are considered to be very safe and lack (in intravenous use) the nephrotoxicity found with iodinated contrast media. Min
https://insights.ovid.com/crossref?an=00002142-200108000-00007
Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill...  Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill...
There is no randomized study carried out in order to compare their pharmacokinetic parameters although midazolam, as a sedative, has been widely administered via continuous infusion as well as intermittent bolus doses in mechanically ventilated critically ill patients. We prospectively investigated the effect of these two principal methods on pharmacokinetic parameters in 23 of mentioned patients (16 males, 7 females) with the mean (± SD) age of 41.22 ± 17.5. All patients received total dose of 72 mg throughout the test days, 9 of whom received 1 mg/h (continuous infusion) and the rest obtained 4 mg / 4 h (intermittent bolus doses). Blood samples were collected at 8 and 4 h prior to the end time of drug administration (zero time), zero time and 4, 8, 12, 20 and 30 h after it. APACHE (Acute Physiology and Chronic Health Evaluation) II required data was recorded daily and the patients mean score was 16.26 ± 4.38. The mean (± SD) value of pharmacokinetic parameters of Midazolam in continuous infusion
http://ijpr.sbmu.ac.ir/article_1319.html
Liposome and protein based stealth nanoparticles  Liposome and protein based stealth nanoparticles
Liposomes and protein based nanoparticles were tuned with different polymers and glycolipids to improve stealth and thus decrease their clearance by macrophages. Liposomes were coated with polyethylene glycol (PEG) and brain-tissue-derived monosialoganglioside (GM1). Bovine serum albumin (BSA) nanoparticles were produced incorporating a PEGylated surfactant (PEG-surfactant). All obtained nanoparticles were monodisperse, with sizes ranging from 80 to 120 nm, with a zeta-potential close to zero. The presented stealth strategies lead to a decrease of internalization levels by macrophages. These surface modified nanoparticles could be used for production of new drug delivery nanosystems for systemic administration (e.g. intravenous application).. ...
http://kth.diva-portal.org/smash/record.jsf?pid=diva2:694656
GMS | 102. Jahrestagung der DOG | Decompensation of intraocular pressure and haemodialysis  GMS | 102. Jahrestagung der DOG | Decompensation of intraocular pressure and haemodialysis
Before haemodialysis the IOP values were always normal but they were markedly increasing (52 mmHg) directly after haemodialysis despite a maximum of local antiglaucomatous therapy. Intravenous applications of acetazolamide rapidly normalised the IOP. Before haemodialysis, we found a metabolic acidosis with low bicarbonate levels which rapidly normalised during haemodialysis. Instead of a further local therapy we started a treatment with intravenous acetazolamide at the beginning and the end of haemodialysis. We first chose a dose of 2x125 mg acetazolamide that was raised to 2x200mg (maximum plasma level 2 hours after dialysis: 35,5 μg/ml). Under this treatment, the IOP was constantly regulated at normal values.. ...
http://www.egms.de/static/de/meetings/dog2004/04dog589.shtml
IDEALS @ Illinois: The toxicity of microcystin-LR in swine and mice  IDEALS @ Illinois: The toxicity of microcystin-LR in swine and mice
Between 12 and 24 min after anesthetized gilts were given a lethal iv dose of purified MCLR (72 $\mu$g/kg), mean aortic and central venous pressures, and renal and hepatic perfusion decreased ($\downarrow$) significantly, while portal venous pressure increased ($\uparrow$) significantly. Significant changes at 45 min included $\uparrow$ bile acids, total bilirubin, lactate, K, and pO$\sb2$, and $\downarrow$ platelet count, base excess, Hct, HCO$\sb3-$, and pCO$\sb2$. At 90 min, significant changes included $\uparrow$ ARG, P, BUN, and creatinine, and $\downarrow$ pH and glucose. Significant changes 150 min postdosing included $\uparrow$ AST, AP, ALT, CPK, and LDH. Livers were markedly enlarged, dark purple-red in color, and readily exuded blood on cut surfaces. Significantly $\uparrow$ liver weights and liver Fe and Hb concentrations were suggestive that 37.9% of the estimated blood volume was present in the liver. The major cause of acute death ($<$5 hr) following iv MCLR dosing in swine is ...
https://www.ideals.illinois.edu/handle/2142/19889
Search  Search
Introduction: Multiple myeloma (MM) is a systemic malignancy of plasma cells defined by monoclonal production of circulating immunoglobulins. Bone pain is a presenting feature in the majority of cases. Treatment may involve intravenous use of bisphosphonates, chemotherapy or haematopoietic stem cell transplantation. Here, we illustrate a first presentation of MM in a patient with mandibular pain and discuss radiographic, diagnostic and treatment challenges of orofacial issues in patients with MM. Case report: A 69-year-old lady presented to an emergency oral surgery clinic with a month-long history of unilateral left-sided pain in her jaw. Examination revealed a buccolingual swelling of 2cm diameter in the lower left premolar region. Radiographic images demonstrated a 2cm lytic lesion in her mandible corresponding with the symptomatic region. Aspiration of the lesion was performed and histological analysis indicated an abundance of atypical plasma cells. Subsequent biopsy revealed sheets of ...
https://www.lenus.ie/handle/10147/122664/discover?rpp=10&filtertype=subject&filter_relational_operator=equals&filter=DENTAL+HEALTH
AnatomyOrganismsDiseasesAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaHealth Care
Administration, OralDrug Administration ScheduleInjections, IntravenousUnited States Food and Drug AdministrationDrug Administration RoutesDose-Response Relationship, DrugRats, Sprague-DawleyTime FactorsAdministration, IntranasalRats, WistarInjections, IntraperitonealDisease Models, AnimalInjections, SubcutaneousAdministration, RectalLiverMice, Inbred C57BLBiological AvailabilityInjections, IntramuscularAdministration, TopicalInfusions, IntravenousHalf-Life
Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety...  Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety...
The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human ... Nasal administration provides a promissory route of administration for EPO [42]. Intranasal rHu-EPO was able to recover ... This molecule is able to reach CNS minimally between 9 and 24 h after intravenous administration [41]. The first clinical ... Before administration, vials were kept at rest room temperature during 50 min. After this time, vials were gently shaken in ...
more infohttps://bmcneurol.biomedcentral.com/articles/10.1186/s12883-017-0908-0
Phenergan intravenous administration  Phenergan intravenous administration
... promethazine intravenous administration promethazine intravenous administration. phenergan intravenous administration ... Phenergan intravenous administration. Phenergan intravenous administration. July 10, 2017 by Filed under Provigil dosage weight ... pyrogen-free solution for deep intramuscular phenergan intravenous administration or intravenous administration. 25-15mg/5ml, ... Phenergan intravenous administration: Para Que Sirve Gemfibrozilo De 300 Mg; Orlistat 120 Mg Com 42 Cpsulas - Neo Quimica - ...
more infohttp://drowsydriving.org/2017/07/phenergan-intravenous-administration
Patent US4447230 - Intravenous administration set assembly - Google Patents  Patent US4447230 - Intravenous administration set assembly - Google Patents
... is disclosed which is capable of introducing fluid from a plurality of sources of intravenous fluids into a patient and which ... to the sources of intravenous fluid. The air-eliminating filter (32) ensures that air or bacteria introduced into the assembly ... The present invention relates to intravenous administration sets in general and, in particular, to intravenous administration ... 1. An intravenous administration set assembly capable of use with at least three differing sources of intravenous fluid ...
more infohttp://www.google.com.au/patents/US4447230
COLOR CODED INTRAVENOUS ADMINISTRATION SET - VENIVEE, INC.  COLOR CODED INTRAVENOUS ADMINISTRATION SET - VENIVEE, INC.
... includes a plurality of liquid intravenous administration sets (32), each administration set (32) defining a flow path from a ... the flow path being bounded over a portion of its length by a flexible intravenous tube (36), and a plurality of indicia, each ... liquid reservoirs containing one of the medicaments and/or nutrients and associated with a respective one of the administration ... A system for the intravenous administration of a plurality of medicaments and/or nutrients contained in respective liquid ...
more infohttp://www.sumobrain.com/patents/wipo/Color-coded-intravenous-administration-set/WO1994025088.html
Veletri (Epoprostenol Powder for Intravenous Administration): Side Effects, Interactions, Warning, Dosage & Uses  Veletri (Epoprostenol Powder for Intravenous Administration): Side Effects, Interactions, Warning, Dosage & Uses
Epoprostenol Powder for Intravenous Administration) may treat, uses, dosage, side effects, drug interactions, warnings, patient ... epoprostenol) Powder for Intravenous (IV) Administration. DESCRIPTION. Epoprostenol sodium is the sodium salt of epoprostenol, ... Administration. VELETRI, once prepared as directed [see Reconstitution], is administered by continuous intravenous infusion via ... home drugs a-z list side effects drug center veletri (epoprostenol powder for intravenous administration) drug ...
more infohttps://www.rxlist.com/veletri-drug.htm
Patent US4476109 - Method of preparing gamma globulin suitable for intravenous administration - Google Patents  Patent US4476109 - Method of preparing gamma globulin suitable for intravenous administration - Google Patents
A method of preparing gamma globulin suitable for intravenous administration comprising a first step of treating a supernatant ... Lyophilized native gamma globulin preparation for intravenous administration. US4276283 *. Sep 10, 1979. Jun 30, 1981. Immuno ... albumin and which is suitable for intravenous administration, comprising the steps of:. mixing together a sample of human blood ... albumin and which is suitable for intravenous administration, comprising the steps of:. mixing together a sample of human blood ...
more infohttp://www.google.com/patents/US4476109?dq=5,960,411
Berinert P Study of Subcutaneous Versus Intravenous Administration - Full Text View - ClinicalTrials.gov  Berinert P Study of Subcutaneous Versus Intravenous Administration - Full Text View - ClinicalTrials.gov
intravenous administration of C1-Inhibitor, after the end of the first observation period (at least after 7 days), each arm ... In case of acute oedema in patients suffering from HAE, the intravenous administration of C1-INH concentrate (e.g., Berinert P ... The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.) administration of Berinert P in ... Berinert P Study of Subcutaneous Versus Intravenous Administration (PASSION). This study has been completed. ...
more infohttps://clinicaltrials.gov/ct2/show/NCT00748202
Duret haemorrhage during intravenous administration of thrombolytic therapy | Neurología (English Edition)  Duret haemorrhage during intravenous administration of thrombolytic therapy | Neurología (English Edition)
Duret haemorrhage during intravenous administration of thrombolytic therapy Hemorragia de Duret durante la perfusión de ... Inicio Neurología (English Edition) Duret haemorrhage during intravenous administration of thrombolytic therapy ... Clinical deterioration and early imaging changes after intravenous tissue plasminogen activator administration in acute ... Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse ...
more infohttps://www.elsevier.es/en-revista-neurologia-english-edition--495-articulo-duret-haemorrhage-during-intravenous-administration-S2173580818301512
Long-term intravenous administration of carboxylated single-walled car | IJN  Long-term intravenous administration of carboxylated single-walled car | IJN
However, the adverse health effects resulting from intravenous injection of SWNTs are not completely understood. Studies have ... Long-term intravenous administration of carboxylated single-walled carbon nanotubes induces persistent accumulation in the ... Long-term intravenous administration of carboxylated single-walled carbon nanotubes induces persistent accumulation in the ... We hypothesized that long-term and repeated intravenous administration of carboxylated SWNTs (c-SWNTs) can result in persistent ...
more infohttps://www.dovepress.com/long-term-intravenous-administration-of-carboxylated-single-walled-car-peer-reviewed-article-IJN
IV Administration | Intravenous Injections | Med-Vet International  IV Administration | Intravenous Injections | Med-Vet International
Med-Vet International carries a wide selection of IV Administration supplies including catheters, extensions and connectors, ... IV administration send medication into a patients bloodstream fast enough. ... During IV administration a catheter is inserted into their patients vein. The catheter allows health care providers to give ... IV administration sends medication into the patients bloodstream. Its useful when a pill/liquid may not get into the ...
more infohttps://www.shopmedvet.com/category/iv-administration
Patent US5224932 - System for intravenous administration of a plurality of medicaments and/or ... - Google Patents  Patent US5224932 - System for intravenous administration of a plurality of medicaments and/or ... - Google Patents
... and/or nutrients contained in respective liquid containers includes a plurality of liquid intravenous administration sets, each ... the flow path being bounded over a portion of its length by a flexible intravenous tube, and a plurality of indicia, each ... administration set defining a flow path from a point of entry adapted to be fluidly connected to a respective liquid container ... liquid reservoirs containing one of the medicaments and/or nutrients and associated with a respective one of the administration ...
more infohttp://www.google.com/patents/US5224932?dq=6,460,050
Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients - Full Text View - ClinicalTrials.gov  Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients - Full Text View - ClinicalTrials.gov
Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients. The safety and scientific validity of ... Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis ( ... single blind clinical trial to assess the safety of the intravenous administration of expanded allogeneic adipose-derived ... Phase Ib/IIa, Escalating Dose, Single Blind, Clinical Trial to Assess the Safety of the i.v Administration of Allogeneic ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT01663116
Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients - Full Text View - ClinicalTrials.gov  Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients - Full Text View - ClinicalTrials.gov
Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients. The safety and scientific validity of ... Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis ( ... single blind clinical trial to assess the safety of the intravenous administration of expanded allogeneic adipose-derived ... Phase Ib/IIa, Escalating Dose, Single Blind, Clinical Trial to Assess the Safety of the i.v Administration of Allogeneic ...
more infohttps://www.clinicaltrials.gov/ct2/show?term=stem+cell+arthritis+AND+Phase&rank=3
Septicaemia resulting from inadvertent intravenous administration of enteral nutrient solution. A case report.  Septicaemia resulting from inadvertent intravenous administration of enteral nutrient solution. A case report.
This report highlights the problem and makes a plea for administration sets that ... Septicaemia caused by inadvertent intravenous administration of enteral nutrition solution (ENS) is a potentially lethal ... This report highlights the problem and makes a plea for administration sets that are not compatible with intravenous cannulas, ... Septicaemia caused by inadvertent intravenous administration of enteral nutrition solution (ENS) is a potentially lethal ...
more infohttp://www.biomedsearch.com/nih/Septicaemia-resulting-from-inadvertent-intravenous/3131887.html
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers - Tabular View - ClinicalTrials.gov  A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers - Tabular View - ClinicalTrials.gov
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers. This study has been completed. ... A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers. ... and injectable diazepam after intravenous (I.V.) administration. Bioavailability is a measure of how much drug is absorbed ... and injectable diazepam after intravenous (I.V.) administration. ... It was approved by the Food and Drug Administration (FDA) for ...
more infohttps://clinicaltrials.gov/ct2/show/record/NCT01364558
Effects of Intravenous Administration of Human Umbilical Cord Blood Stem Cells in 3-Acetylpyridine-Lesioned Rats  Effects of Intravenous Administration of Human Umbilical Cord Blood Stem Cells in 3-Acetylpyridine-Lesioned Rats
... Lucía ... Lucía Calatrava-Ferreras, Rafael Gonzalo-Gobernado, Antonio S. Herranz, et al., "Effects of Intravenous Administration of Human ...
more infohttps://www.hindawi.com/journals/sci/2012/135187/cta/
Effects of Intravenous Administration of Human Umbilical Cord Blood Stem Cells in 3-Acetylpyridine-Lesioned Rats  Effects of Intravenous Administration of Human Umbilical Cord Blood Stem Cells in 3-Acetylpyridine-Lesioned Rats
As shown here, intravenous administration of HuUCBMCs significantly raised the phospho-Akt/Akt ratio in the cerebellum and ... Effects of Intravenous Administration of Human Umbilical Cord Blood Stem Cells in 3-Acetylpyridine-Lesioned Rats. Lucía ... S. Garbuzova-Davis, A. E. Willing, T. Zigova et al., "Intravenous administration of human umbilical cord blood cells in a mouse ... Here, we report that intravenous administration of HuUCB mononuclear cells (HuUCBMCs) reaches the cerebellum and brain stem of ...
more infohttps://www.hindawi.com/journals/sci/2012/135187/
Intravenous Administration of ONYX-015, a Selectively Replicating Adenovirus, Induces Antitumoral Efficacy | Cancer Research  Intravenous Administration of ONYX-015, a Selectively Replicating Adenovirus, Induces Antitumoral Efficacy | Cancer Research
Intravenous Administration of ONYX-015, a Selectively Replicating Adenovirus, Induces Antitumoral Efficacy. Carla C. Heise, ... Intravenous Administration of ONYX-015, a Selectively Replicating Adenovirus, Induces Antitumoral Efficacy ... Intravenous Administration of ONYX-015, a Selectively Replicating Adenovirus, Induces Antitumoral Efficacy ... Intravenous Administration of ONYX-015, a Selectively Replicating Adenovirus, Induces Antitumoral Efficacy ...
more infohttp://cancerres.aacrjournals.org/content/59/11/2623
Metabolism and disposition of 1-bromopropane in rats and mice following inhalation or intravenous administration | RTI  Metabolism and disposition of 1-bromopropane in rats and mice following inhalation or intravenous administration | RTI
Metabolism and disposition of 1-bromopropane in rats and mice following inhalation or intravenous administration. ... or intravenous administration (5, 20, and 100 mg/kg). [1,2,3-(13)C]1-BrP and [1-(14)C]1-BrP were administered to enable ... Metabolism and disposition of 1-bromopropane in rats and mice following inhalation or intravenous administration. Toxicology ... and tissues were collected for up to 48 h post-administration for determination of radioactivity distribution. Rats and mice ...
more infohttps://www.rti.org/publication/metabolism-and-disposition-1-bromopropane-rats-and-mice-following-inhalation-or
Chitosan: A Biocompatible Material for Oral and Intravenous Administrations | Springer for Research & Development  Chitosan: A Biocompatible Material for Oral and Intravenous Administrations | Springer for Research & Development
Hirano S., Seino H., Akiyama Y., Nonaka I. (1990) Chitosan: A Biocompatible Material for Oral and Intravenous Administrations. ... that chitosan is usable as a novel carrier of drugs in the drug delivery system for oral and intravenous administration. ...
more infohttps://rd.springer.com/chapter/10.1007/978-1-4899-0768-4_28
AnatomyOrganismsDiseasesAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaHealth Care
Administration, OralDrug Administration ScheduleInjections, IntravenousUnited States Food and Drug AdministrationDrug Administration RoutesDose-Response Relationship, DrugRats, Sprague-DawleyTime FactorsAdministration, IntranasalRats, WistarInjections, IntraperitonealDisease Models, AnimalInjections, SubcutaneousAdministration, RectalLiverMice, Inbred C57BLBiological AvailabilityInjections, IntramuscularAdministration, TopicalInfusions, IntravenousHalf-LifeAdministration, IntravenousDrug InteractionsArea Under CurveInjections, Intraventricular
Suitable for intravenousInjectionsEfficacyPluralityTumorAntibioticExposureAdverseSterilePeripheralVersusMedicationInfectionDosageTissuePreparationsFluidIntranasalLungRouteInhibitorDrugSystemicOralHighDrugsDaysSetsDistribution
Suitable for intravenous2search
  • A method of preparing gamma globulin suitable for intravenous administration comprising a first step of treating a supernatant liquid separated from human blood plasma with ethanol under conditions of a pH of 5.5 to 6.5, an ethanol concentration of 30 to 35%, and a protein concentration of 1 to 2% by. (google.com)
  • Immunoglobulin preparations have been available for therapeutic parenteral use for over four decades, although those suitable for intravenous use (IVIg) have only been manufactured for the last 10 years. (alpfmedical.info)
Injections2search
Efficacy3search
Plurality2search
  • An intravenous administration set assembly (10) is disclosed which is capable of introducing fluid from a plurality of sources of intravenous fluids into a patient and which allows the various sources of fluid to be easily attached and detected from the assembly without the necessity for intravening. (google.com.au)
  • An intravenous administration set assembly (10) is disclosed which is capable of introducing fluid from a plurality of sources of intravenous fluids into a patient and which allows the various sources of fluid to be easily attached and detected from the assembly without the necessity for intravening safety steps, such as purging the system, and yet without any possibility of air or bacteria being introduced through the system into the patient. (google.com.au)
Tumor2search
Antibiotic2search
Exposure3search
  • Protein levels of type-I and type-III collagens, matrix metalloproteinase-2, and the tissue inhibitor of metalloproteinase-2 were upregulated after intravenous exposure to c-SWNTs as determined by immunohistochemical assays and Western blotting, which suggested collagen deposition and remodeling of the extracellular matrix. (dovepress.com)
  • In addition, i.v. administration might also cause toxicity because of the exposure of normal cells to virus. (aacrjournals.org)
  • In this study, the factors influencing the disposition and biotransformation of 1-BrP were examined in male F344 rats and B6C3F1 mice following inhalation exposure (800 ppm) or intravenous administration (5, 20, and 100 mg/kg). (rti.org)
Adverse2search
Sterile2search
Peripheral1search
  • Furthermore, other studies have assayed the potential therapeutic activity of intracerebroventricular, peripheral, or intranasal administration of neurotrophic factors such as insulin-like growth factor (IGF-I), or glial-derived growth factor (GDNF), in different experimental models of cerebellar ataxia in rodents [ 9 - 13 ]. (hindawi.com)
Versus2search
Medication1search
Infection1search
Dosage2search
Tissue1search
  • We present the case of a patient who died after a massive brainstem haemorrhage, possibly secondary to a transtentorial herniation (Duret haemorrhage) during treatment of a proximal occlusion of the right middle cerebral artery (MCA) with intravenous recombinant tissue plasminogen activator (rt-PA). (elsevier.es)
Preparations1search
Fluid2search
  • An air-eliminating filter (32) is attached to a manifold formed of fittings (26) which are connected through inlet adapters (28) to the sources of intravenous fluid. (google.com.au)
  • 3. An intravenous administration set assembly as claimed in claim 2 wherein the tubing means (38, 46, 56) further includes a second fitting (40) having an inlet adapter (43) provided thereon which is capable of being locked to a source of biological fluid for introduction to a patient which may not pass through an air-eliminating filter. (google.com.au)
Intranasal1search
  • This study will evaluate two intranasal (nasal spray) formulations of diazepam which will be supplied by Neurelis, Inc. The purpose of this clinical research study is to assess the bioavailability and pharmacokinetics of two formulations of diazepam after intranasal (nasal spray) and injectable diazepam after intravenous (I.V.) administration. (clinicaltrials.gov)
Lung1search
Route2search
Inhibitor1search
Drug2search
Systemic2search
Oral5search
High3search
Drugs1search
Days1search
  • Following intravenous administration, lotilaner had a low clearance of 0.13 l/kg/day, large volumes of distribution V z and V ss of 5.34 and 5.37 l/kg, respectively and a terminal half-life of 28.7 days. (springer.com)
Sets1search
  • This report highlights the problem and makes a plea for administration sets that are not compatible with intravenous cannulas, and more stringent national bacteriological standards of preparation of ENS. (biomedsearch.com)
Distribution1search
  • Exhaled breath volatile organic chemicals (VOC), exhaled CO(2), urine, feces, and tissues were collected for up to 48 h post-administration for determination of radioactivity distribution. (rti.org)